TITLE PAGE

Title: Does flare trial design affect the effect size of non-steroid anti-inflammatory drugs in symptomatic osteoarthritis? A systematic review and meta-analysis.

Authors: Smith TO, Zou K, Abdullah N, Chen X, Kingsbury SR, Doherty M, Zhang W, Conaghan PG.

Affiliations:

Toby O Smith BSc (Hons), MSc, MA, PhD, MCSP – University Lecturer, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK

Kun Zou, PhD – Post-Doctorial Researcher, Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, UK

Natasya Abdullah, MD - Post-Doctorial Researcher, Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, UK

Xi Chen, PhD - Post-Doctorial Researcher, Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, UK

Sarah R Kingsbury BSc (Hons), PhD - Osteoarthritis Strategic Project Lead, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, UK.

Michael Doherty MA MD FRCP - Professor of Rheumatology and Head of Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, UK Weiya Zhang BMed BPH, MEpi, PhD - Professor of Epidemiology, Faculty of Medicine & Health Sciences, University of Nottingham, UK.

Philip G Conaghan MB BS PhD FRACP FRCP – Professor of Musculoskeletal Medicine, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, UK.

Corresponding Author: Professor Philip Conaghan, NIHR Leeds Musculoskeletal Biomedical Research Unit, Section of Musculoskeletal Disease, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, United Kingdom. Email: <u>p.conaghan@leeds.ac.uk</u>; Tele +44 (0) 113 3924883

ABSTRACT

Objectives: It is thought that the clinical trial benefits of oral non-steroid anti-inflammatory drugs (NSAIDs) may relate to flare designs. The aim of this study was to examine the difference in NSAID (including COX-2 inhibitors) response in osteoarthritis (OA) trials based on different designs.

Methods: Systematic review was undertaken of the databases MEDLINE, EMBASE, AMED, CINAHL and the Cochrane library to February 2015. Randomised controlled trials assessing pain, function and/or stiffness following commencement of NSAIDs in flare and non-flare designs were eligible. Trials were assessed using the Cochrane Risk of Bias tool. Meta-analyses were conducted to assess the effect sizes of NSAIDs for OA with flare versus non-flare trial designs.

Results: Fifty-seven studies including 33,263 participants assessing 26 NSAIDs were included. Twenty-two (39%) were flare design, 24 (42%) were non-flare designs, 11 (19%) were possible flare designs. On meta-analysis, there was no statistically significant difference in effect size of NSAIDs versus placebo between flare and non-flare trial designs for absolute pain and function or stiffness at immediate (1 week), short (2 to 4 week) or longer (12 to 13 week) follow-up periods (p>0.05). However there was a lower effect size for mean change in pain in flare and possible flare trials compared to non-flare trials at short-term follow-up (0.36 versus 0.69; p=0.05).

Conclusions: Contrary to previous understanding, flare trial designs do not result in an increased treatment effect for NSAIDs in people with OA compared to non-flare design. Whether flare design influences other outcomes such as joint effusion remains unknown.

Keywords: Randomised Controlled Trial; NSAIDs; Osteoarthritis; Effect Size; Methodology

INTRODUCTION

Osteoarthritis (OA) is a debilitating musculoskeletal disorder which symptomatically affects approximately 10% of the population aged over 60 years, and increases with age [1,2]. The most commonly affected joints are the hands, feet, knees and hips, with principle manifestations being pain, stiffness and resultant loss of function and independence [3]. The optimal treatment for people with OA combines both pharmacological and non-pharmacological treatments [4]. Nonsteroidal anti-inflammatory drugs (NSAIDs and selective cyclooxygenase-2 inhibitors) are the most commonly used painkillers for people with OA in Europe and the USA with 20% to 35% of the OA population reporting their use [5,6].

Flare design trials have been commonly used to assess the efficacy of NSAIDs. They are defined as trials which have recruited patients with increased pain after ceasing their usual pharmacological treatment [7]. Accordingly, these participants may respond differently to the general OA population with respect to the therapy under investigation. This may be of particular importance if only those who have previously responded to a NSAID are recruited to a trial investigating NSAID efficacy, inflating the effect size compared to an unselected OA group.

Trijau et al [8] previously presented a well-designed meta-analysis comparing the efficacy of NSAIDs in flare and non-flare design trials. They reported that flare trials evaluating NSAIDs resulted in a higher magnitude of treatment effect compared to non-flare trials. However, a large number of relevant papers have been published since the March 2009 search date in that publication. Our aim was therefore to conduct a contemporary systematic literature review investigating the effects of flare design trials on the efficacy of NSAIDs for people with OA and then to perform a meta-regression to examine the effects of other possible factors including study setting, allocation concealment and sample size on outcomes.

METHODS

Search Strategy

A search strategy was undertaken of the published databases: MEDLINE, EMBASE, AMED, CINAHL and the Cochrane library. The search was undertaken from database inception to 1st February 2015. A review of the potentially included papers' reference lists and previous review articles was undertaken to identify any additional studies. The search terms for the MEDLINE search are presented in Supplementary Table 1. These were amended for the other search databases. We did not exclude papers based on year or language of publication.

Identification of Studies

All randomised placebo controlled trials assessing the efficacy of NSAIDs in people with OA were included. Flare design was defined as trials where participants were only eligible when they had increased pain after ceasing their usual treatment before entering the trial [7]. Where there was uncertainty regarding the magnitude of this increased pain but there was sufficient evidence to suggest that these could have been flare design trials, the studies were included and termed 'possible flare design' trials. Where there was no reference to 'flare trial design' and it was clear a non-flare trial design was adopted, these were defined as 'non-flare design' trials. Participants with OA of any joint or multiple joints were included. OA was defined according to the American College of Rheumatology (ACR) criteria, radiological and/or clinical diagnosis [9]. The interventions included all NSAIDs (conventional and COX-2 inhibitors).

Outcomes

The primary outcome was pain. Pain could be measured by visual analogue scale (VAS) or numerical rating scale (NRS) methods, or as a sub-domain of an overall scoring system such as the Western Ontario and McMaster Universities Arthritis Index (WOMAC)[10]. Where pain was assessed using a number of different measures, we selected the scale according to the hierarchy of the outcomes suggested by Juhl et al [11]. Secondary outcome measures were function and stiffness.

Outcomes were assessed at specific follow-up periods. These were classified *a priori* as: immediate, short or longer-term. Immediate term outcomes were defined as outcomes within the first week of commencing the trial; short term was defined as two to four weeks following commencement, and longer-term outcomes were defined as six weeks and over.

Data Extraction

Data were extracted by one reviewer (KZ) and validated by three others (NA, XC, TS). Any disagreements were resolved through discussion with a fifth reviewer (WZ). Data were extracted onto a pre-defined database and included: country of origin, sample size, gender, age, BMI, setting (community or hospital-based), NSAID medication (type, dose, frequency, duration, route of delivery), placebo comparison, follow-up intervals and period, baseline and follow-up outcomes.

Critical Appraisal

Each included trial was assessed for methodological quality using the Cochrane Risk of Bias tool [12]. Trial design was assessed using the five criteria: random sequence generation, allocation concealment, blinding to participants, blinding to outcome assessment, withdrawals (attrition bias) and selective reporting (reporting bias).

Statistical Methods

Study heterogeneity was assessed through visual assessment of the participant characteristics, trial design, NSAIDs and placebo approaches and outcome measures. Where there was evidence of trial homogeneity, a meta-analysis was undertaken.

Heterogeneity was measured using I² index and Chi-squared test. Where I² was 30% or above and Chi-squared $p \le 0.10$, a random-effects meta-analysis was undertaken. When I² was less than 30% and Chi-squared p > 0.10, a fixed effects meta-analysis was undertaken. All meta-analyses were undertaken by two reviewers (TS, KZ) and interpreted by four reviewers. Through this we assessed the effect size (ES) (standard mean difference between NSAID versus placebo interventions) overall and at each time point (immediate, short, longer-term). Clinically, an effect size of 0.2 suggested a small effect, 0.5 meant a

moderate effect and 0.8 and over indicated a large effect. The analysis of flare versus non-flare trial design was then made to assess for differences between these two subgroups of the NSAID data, presenting this with Chi-square p-values and I² statistics between the two pooled effect sizes. A sensitivity analysis was also undertaken to compare 'flare design' or 'possible flare designs' for each time point.

A meta-regression analysis (random-effects model) was undertaken to confirm whether flare design affected pain and other clinical outcomes given the adjustment for setting (community-based), allocation concealment, intention-to-treat analysis and whether there was more than or less than 100 participants per study arm, as suggested by Nüesch et al [13]. These are the common factors that may affect the results from RCTs and that may confound the difference between flare and non-flare designs. The partial regression coefficient (β) was used to present the contribution of each variable. A funnel plot was constructed to assess for publication bias [14].

All data were presented with 95% confidence intervals (CI) and with forest-plots. A two-sided p-value of < 0.05 was considered statistically significant. Analyses were undertaken using RevMan (Review Manager). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011) and STATA (version 14.0, STATA Corp, Dallas, Texas, USA).

RESULTS

Characteristics of included studies

A total of 8,592 citations were identified from the search. Of these 57 were eligible and included in the meta-analysis (Supplementary Figure 1). Of the 57 trials, 22 (39%) were 'flare designs', 24 (42%) were 'non-flare designs' and 11 (19%) were 'possible flare designs' (Supplementary Tables 2 and 3). Of the 22 flare designs, 20 (91%) were funded by industry and two were unclear about funding source. In the 24 non-flare trial designs, 10 (42%) were funded by industry, two were funded by public funding (8%), and 13 remained unclear about funding source.

A total of 33,263 participants were included in the review (10,480 men/21,877 women). Two studies did not provide the gender composition of their cohort [15,16]. Mean age ranged from 53.5 [17] to 83 years [18]. The duration of NSAID/placebo intervention ranged from one week [19,20] to 26 weeks [21]. Thirty studies were for knee OA, four for hip OA, 21 for hip and knee OA, and two for hand OA. The mean duration of OA was documented in 31 papers. This ranged from 2.2 years [22] to 15 years [18]. Trials were conducted in a hospital setting in 36 studies, in the community in two studies, whilst unclear in 19 papers.

Critical Appraisal

In general, the quality of studies was higher in the flare designs than the non-flare or possible flare design trials (Supplementary Table 4). There was a higher proportion of papers which clearly designed the randomisation, blinded of their assessors, and assessed a minimum of 85% of their cohort in the flare compared to non/possible flare trials. The quality of studies was comparable between the non-flare and possible flare trials.

Publication Bias

As presented in Supplementary Figure 2 there was some evidence of small sample size publication bias in the non-flare designs but not in flare designs. That is, studies with smaller sample size were more likely to produce larger effect size and they were more likely to be published in non-flare trials.

Primary outcome: Pain

There was no statistically significant difference in effect size between flare and non-flare trial design for pain as measured by mean change in pain score (p=0.08; I²=66.4%; Figure 1; Table 1) or absolute pain score (p=0.23; I²=29.4%; Figure 2) These findings remained when the data were analysed by follow-up period for the flare versus non-flare trials (Table 2). There were two exceptions to this. There was a lower effect size in flare and possible flare trial designs in mean change in pain score at shortterm follow-up compared to non-flare trial designs (ES: 0.36 vs. 0.69; p=0.05; I²=73.3%; Table 3), although this presented with high statistical heterogeneity. Conversely there was a statistically significant difference between flare and possible flare trials for absolute pain score at longer-term follow-up, being greater in flare trial designs (ES: 0.85 vs. 0.40; p=0.05; I^2 =74.0%), and in the flare and non-flare trials for the same outcome at the same follow-up period (ES: 0.44 vs. 0.00; p<0.01; I^2 =90.2%).

Secondary outcomes: Function

There was no statistically significant difference in effect size between flare and non-flare trial design for function as measured by mean change (p=0.54; $I^2=0\%$; Table 1) or absolute functional scores (p=0.08; $I^2=67.4\%$). However, when assessed by follow-up period, there was a statistical difference for immediate-term follow-up analysis with greater effect sizes in mean change in functional scores for non-flare trial designs compared to flare trial papers (ES: 0.26 vs. 0.47; p=0.04; $I^2=75.6\%$; Table 2). This was also evident for the short-term follow-up in the flare and possible flare trial designs versus non-flare trial designs (ES: 0.28 vs. 0.68; p<0.01; $I^2=93.5\%$; Table 3), and in the longer-term follow-up (ES: 0.35 vs. 0.55; p=0.01; $I^2=84.9\%$; Table 3). There was no statistically significant difference between flare versus non-flare (Table 2) and flare/possible flare trial designs versus non-flare trial design for absolute functional score (Table 3).

Secondary outcomes: Stiffness

There was no statistically significant difference in effect size between flare and non-flare trial design for stiffness as measured with mean change in functional scores (p=0.75; $I^2=0\%$; Table 1) or absolute stiffness scores (p=1.00; $I^2=0\%$). There was no statistically significant difference in effect size between flare and non-flare or flare and possible flare compared to non-flare trial designs for stiffness as measured with mean change from baseline to any follow-up interval or absolute score (Table 2; Table 3). The only exception was for non-flare trial designs which demonstrated a greater effect size for absolute stiffness score compared to flare and possible flare trial designs on immediate-term follow-up analysis (ES: 0.22 vs. 0.84; p=0.01; $I^2=86.3\%$; Table 3).

Meta-Regression

The results of the meta-regression are presented in Table 4. This analysis confirmed that flare design had similar results as non-flare designs, given the adjustment for the five major study-level confounding factors (study setting, allocation concealment, ITT, blinding to participants and ≥ 100 participants per trial arm).

DISCUSSION

The findings of this paper indicate that there is no significant difference between flare and non-flare trial designs for NSAIDs versus placebo when assessed in people with OA. Mean change in pain at short-term follow-up was significantly higher in non-flare than flare and possible flare trial designs. These results differ to previous findings [8]. The current study included an increased number of trials: whilst the earlier paper assessed 33 studies, all of which were included in the current analysis, an additional 24 trials contributed to our analysis. Furthermore, we conducted a meta-regression analysis to adjust for other variables that may have influenced the outcome and confirmed that the flare design had indeed no impact on results. Both our analysis and Trijiau et al's [8] adopted a similar definition of flare trial design; hence this was not a potential source of difference between the analyses. Similarly, the new trials included since Trijau et al's [8] meta-analysis did not differ in terms of duration, patient numbers or characteristics.

Previous studies have suggested that flare study designs may be a more efficient trial design when investigating NSAIDs in people with OA [7,8]. This has been justified through reported higher treatment effect conferred through flare designs. It was suggested that flare trial design may be valuable to assess the efficacy of a NSAID without the additional effects of other analgesics (current or recently previous) affecting outcome, to provide higher discriminant capacity, thus allowing sufficiently powerful analyses from smaller sample sizes [8]. Accordingly, such NSAIDs may be more likely to provide change in pain scores ranging from 30% to 70% which is the most sensitive change on the "S" curve of pain response. However, the current results question the value of the flare design.

The statistical analysis indicated small sample size publication bias, especially for non-flare designs, which tended to have smaller sample size, therefore more likely to produce larger effect sizes (Supplementary Figure 2). This may partially explain the reason why non-flare designs had larger pain reduction than flare designs in the short-term. Should this publication bias be excluded, it is likely that flare and non-flare designs have no difference in the short-term.

One explanation for trials which found a difference between flare and non-flare trial design may be attributed to recruitment or trial selection bias. Consideration should be given to whether flare trial designs recruit a certain phenotype of patient. It may be that flare trial designs recruit NSAID responders with a more 'inflammatory' phenotype of OA. In such instances, these participants, when ceasing their usual medications, and particularly NSAIDs, would be recruited as their pain could flare within the specified wash-out period. Conversely, those with more mechanically-related OA pain may not have the same change in pain scores on discontinuing NSAIDs, and therefore be excluded. However, they may also increase the chances of detecting a 'regression to the mean' as even if no treatment is provided, pain which has 'flared up' could naturally subside. This may therefore be considered a substantial limitation to this study design.

A second possible explanation for our findings is that participants whose pain increases following cessation of current analgesia may gain more pain relief not just from their NSAID but also from the placebo intervention. This is conceivable since participants in both trial arms in the flare study design might have an increased expectancy, a major driver of placebo/contextual response [23] through previous experience of the positive effects from their medications. Consequently there would be no difference between the two trial arms for flare-trials, i.e. no inflation of effect size calculated on the separation of treatment from the placebo intervention, compared to the difference between treatment and placebo arms in non-flare trials.

The included papers poorly documented the frequency to which their participants presented with joint effusion, or how the presence of effusion changed with stopping treatment. Maricar et al [24] found mixed results about whether clinically-detected joint effusion is a significant predictor of pain outcome

following intra-articular steroid injection in people with knee OA. Modern imaging studies suggest clinical detection of synovitis at the knee is not very accurate [25], and since synovitis is extremely common in knee OA [25] (the most prevalent joint in this analysis), it is very likely that most participants in the included studies had synovitis, though of varying degree. The accurate detection of synovitis volume or activity may in future identify a responsive subgroup to anti-inflammatory therapy within the OA population [26].

There are limitations to this work which should be considered when interpreting these findings. Firstly, the analysis was based on study-level analysis. Accordingly it was not possible to account for potential variation between patients at an individual patient data level. Secondly, whilst we adopted a clear definition of flare design based on current recommendations [7], the exact nature of the trial design was unclear in 11 papers (19%). To adjust for this potential classification-based uncertainty, we analysed 'possible flare designs' separately in a sensitivity analysis, which did not change the overall findings. Thirdly data in this analysis were only based on NSAIDs. It is therefore not possible to generalise these findings to other analgesics, which may have a different response to pain and inflammatory components to specific patient's presenting OA. Fourthly the included trials did not state which medications their participants stopped at study entry, that is, whether they stopped NSAIDs or other analgesics. If the majority of participants stopped NSAIDs, the implication is that stopping NSAID response predicts NSAID response in flare trials. This possibility is supported by a recent European survey suggesting that NSAIDs are used in nearly 60% of the OA population [5]. However, conversely a large proportion of participants (40%) would have stopped other analgesics. This subgroup may therefore have not been eligible for flare-trials, thereby potentially accounting for a difference between flare/non-flare trials. Limited information on which medications were ceased on study entry, precludes this analysis. Finally, the analyses were based on randomised controlled trial cohorts, and therefore homogenous, selfselecting populations. This loses diversity of the wider, general public, which may reduce the clinical sensitivity and generalisability to answer the research question.

To conclude, the results from this meta-analysis suggest there is no statistically significant difference in effect size in pain, function or stiffness for flare compared to non-flare trials in the assessment of NSAID efficacy for people with OA, with some evidence indicating an increase in treatment effect detected in non-flare trial designs. Consideration should be made by industrial and non-industrial researchers on their rationale for using flare trial design, based on these results.

DECLARATION OF SOURCES OF FUNDING AND ACKNOWLEDGEMENTS

Acknowledgement: None.

Contributors: PC and WZ conceptualised the study. PC, WZ and TS contributed to the design of the study. TS, KZ and WZ conducted the analysis. All authors contributed to data collection, interpretation of research findings and manuscript writing.

Sources of Funding and **Conflicts of interest**: PGC and SRK are part-funded through the National Institute for Health Research (NIHR) though the Leeds Musculoskeletal Biomedical Research Unit. WZ had grants from Nottingham-China Scholarship, during the conduct of the study; MD reports personal fees from Ad hoc advisory boards for osteoarthritis and gout for AstraZeneca, Menarini, Nordic Biosciences, Pfizer, outside the submitted work; no other relationships or activities that could appear to have influenced the submitted work.

Role of Funding Source: Dr Zou was supported by the International Scholarship for Research Excellence from the University of Nottingham. Dr Chen was funded by the Nottingham Arthritis Research UK Pain Centre. The funding organisations did not participant in the study design, data collection, analysis, interpretation of data and report.

REFERNCES

1. Menz HB, Roddy E, Marshall M, et al. Demographic and clinical factors associated with radiographic severity of first metatarsophalangeal joint osteoarthritis: cross-sectional findings from the Clinical Assessment Study of the Foot. *Osteoarthritis Cartilage* 2015;23:77-82.

2. Turkiewicz A, Gerhardsson de Verdier M, et al. Prevalence of knee pain and knee OA in southern Sweden and the proportion that seeks medical care. *Rheumatology* 2014;54:827-835

3. March L, Smith EU, Hoy DG, et al. Burden of disability due to musculoskeletal (MSK) disorders. *Best Pract Res Clin Rheumatol* 2014;28:353-366.

4. National Institute for Health and Care Excellence (NICE). Osteoarthritis: Care and Management in Adults - 2014. Accessed on 09.12.2014. Available at: http://www.nice.org.uk/guidance/CG177

5. Kingsbury SR, Gross HJ, Isherwood G, et al. Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries. *Rheumatology* 2014; 53:937-947.

6. Kingsbury SR, Hensor EM, Walsh CA, et al. How do people with knee osteoarthritis use osteoarthritis pain medications and does this change over time? Data from the Osteoarthritis Initiative. *Arthritis Res Ther* 2013;15:R106.

7. Cooper C, Adachi JD, Bardin T, et al. How to define responders in osteoarthritis. *Curr Med Res Opin* 2013;29:719–729.

8. Trijau S, Avouac J, Escalas C, et al. Influence of flare design on symptomatic efficacy of nonsteroidal anti-inflammatory drugs in osteoarthritis: a meta-analysis of randomized placebo-controlled trials. *Osteoarthritis Cartilage* 2010;18:1012-1018.

9. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. *Arthritis Rheum* 1991;34:505-514.

10. Bellamy N. WOMAC Osteoarthritis Index User Guide. Version V. Brisbane, Australia 2002

11. Juhl C, Lund H, Roos EM, et al. A hierarchy of patient-reported outcomes for meta-analysis of knee osteoarthritis trials: empirical evidence from a survey of high impact journals. *Arthritis* 2012;136245.

12. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane Handbook for systematic reviews of interventions. Wiley-Blackwell, Chichester, West Sussex, 2008;187-242.

13. Nüesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. *BMJ* 2010;341:c3515.

14. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-634.

15. Pincus T, Koch G, Lei H, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): Two randomised, double blind, placedo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. *Ann Rheum Dis* 2004;63:931-939.

16. Bourgeois P, Dreiser RL, Lequesne MG, et al. Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. *Europ J Rheumatol Inflam* 1994;2:39-50.

17. Paul S, Das N, Ghosh S. The effects of aceclofenac and nabumetone in osteoarthritis. *JNMA J Nepal Med Assoc* 2009;48:121-125.

18. Truitt KE, Sperling RS, Ettinger WH, Jr., et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. *Aging Clin* 2001;13:112-121.

19. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. *Mayo Clinic Proceedings*. 1999;74:1095-1105.

20. Wittenberg RH, Schell E, Krehan G, et al. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebocontrolled comparison with celecoxib [NCT00267215]. *Arthritis Res Therap* 2006;8:R35.

21. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: A randomized clinical trial. *J Rheumatol* 1998;25:2203-2212.

22. Nunes CP, De Oliveira PC, De Oliveira JM, et al. A double-blind, comparative, placebocontrolled study in two arms of the safety and efficacy of the anti-inflammatory and analgesic action of the association of cyanocobalamin, pyridoxine chlorihydrate, thiamine mononitrate and diclofenac sodium in tablets, in patients with osteoarthritis. *Revista Brasil Med* 2005;62:486-491.

23. Doherty M, Dieppe PA. The "placebo" response in osteoarthritis and its implications for clinical practice. *Osteoarthritis Cartilage* 2009; 17:1255-62.

24. Maricar N, Callaghan MJ, Felson DT, et al Predictors of response to intra-articular steroid injections in knee osteoarthritis--a systematic review. *Rheumatology* 2013;52:1022-1032.

25. Conaghan P, D'Agostino MA, Ravaud P, et al. EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 2: exploring decision rules for clinical utility. *Ann Rheum Dis* 2005;64:1710-1714.

26. Keen HI, Hensor EM, Wakefield RJ et al. Ultrasound assessment of response to intra-articular therapy in osteoarthritis of the knee. *Rheumatology* 2015;54:1385-1391.

27. Roemer FW, Kassim Javaid M, Guermazi A, et al. Anatomical distribution of synovitis in knee osteoarthritis and its association with joint effusion assessed on non-enhanced and contrastenhanced MRI. *Osteoarthritis Cartilage* 2010;18:1269-1274.

28. Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. *J Rheumatol* 1998;25:1602-1611.

29. Ehrich EW, Schnitzer TJ, McIlwain H, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib. *J Rheumatol* 1999;26:2438-2447.

30. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. *Arch Intern Med* 2000;160:1781-1787.

31. Ehrich EW, Bolognese JA, Watson DJ, et al. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. *Am J Managed Care* 2001;7:609-616.

32. McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee: A placebo-controlled, randomised, double-blind comparison. *Scand J Rheumatol* 2001;30:11-18.

33. Williams GW, Hubbard RC, Yu SS, et al. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. *Clin Therap* 2001;23:213-227.

34. Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. *Curr Med Res Opin* 2002;18:49-58.

35. Grifka JK, Zacher J, Brown JP, et al. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. *Clin Experiment Rheumatol* 2004;22:589-596.

36. Fleischmann R, Sheldon E, Maldonado-Cocco J, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. *Clin Rheumatol* 2005;25:42-53.

37. Wiesenhutter CW, Boice JA, Ko A, et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. *Mayo Clinic Proceedings* 2005;80:470-479.

38. Bingham ICO, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. *Rheumatology* 2007;46:496-507.

39. Wittenberg RH, Schell E, Krehan G, et al. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebocontrolled comparison with celecoxib [NCT00267215]. *Arthritis Res Therap* 2006;8:R35.

40. Puopolo A, Boice JA, Fidelholtz JL, et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. *Osteoarthritis Cartilage* 2007;15:1348-1356.

41. Reginster Y, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. *Ann Rheum Dis* 2007;66:945-951.

42. Rother M, Lavins BJ, Kneer W, et al. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral cefecoxib and placebo in osteoarthritis of the knee: Multicentre randomised controlled trial. *Ann Rheum Dis* 2007;66:1178-1183.

43. Karlsson J, Pivodic A, Aguirre D, et al. Efficacy, safety, and tolerability of the cyclooxygenaseinhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. *J Rheumatol* 2009;36:1290-1297.

44. Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. *Pain* 2009;143:238-245.

45. Baerwald C, Verdecchia P, Duquesroix B, et al. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. *Arthritis Rheum* 2010;62:3635-3644.

46. Cryer BL, Sostek MB, Fort JG, et al. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials. *Ann Med* 2011;43:594-605.

47. Schnitzer TJ, Dattani ID, Seriolo B, et al. A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis. *Clin Rheumatol* 2011;30:1433-1446.

48. Essex MN, O'Connell M, Bhadra Brown P. Response to nonsteroidal antiinflammatory drugs in African Americans with osteoarthritis of the knee. *J Internat Med Res* 2012;40:2251-2266.

49. El-Mehairy MM, Shaker A, Bahgat NE, et al. A double-blind comparison of niflumic acid with phenylbutazone, oxyphenylbutazone and placebo in the treatment of osteoarthrosis. *Rheumatol Rehabil* 1974;13:198-203.

50. Shipley M, Berry H, Broster G, et al. Controlled trial of homoeopathic treatment of osteoarthritis. *Lancet* 1983;1:97-98.

51. Lee P, Davis P, Prat A. The efficacy of diflunisal in osteoarthritis of the knee. A Canadian multicenter study. *J Rheumatol* 1985;12:544-548.

52. Dreiser RL, Gersberg M, Thomas F, et al. Ibuprofen 800 mg for the treatment of osteoarthritis of the interphalangeal joints of the hand or trapezo metacarpal joint. *Revue du Rhumatisme* 1993;60:719-724.

53. Nguyen M, Dougados M, Berdah L, et al. Diacerhein in the treatment of osteoarthritis of the hip. *Arthritis Rheumat* 1994;37:529-536.

54. Sandelin J, Harilainen A, Crone H, et al. Local NSAID gel (Eltenac) in the treatment of osteoarthritis of the knee: A double blind study comparing eltenac with oral diclofenac and placebo gel. *Scand J Rheumatol* 1997;26:287-292.

55. Lund B, Distel M, Bluhmki E. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. *Scand J Rheumatol* 1998; 27:32-37.

56. Davies GM, Watson DJ, Bellamy N. Comparison of the responsiveness and relative effect size of the Western Ontario and McMaster Universities Osteoarthritis Index and the Short-Form Medical Outcomes Study Survey in a randomized, clinical trial of osteoarthritis patients. *Arthritis Care Res* 1999;12:172-179.

57. Schmitt W, Walter K, Kurth HJ. Clinical trial on the efficacy and safety of different diclofenac formulations: Multiple-unit formulations compared to enteric coated tablets in patients with activated osteoarthritis. *Inflammopharmacol* 1999;7:363-375.

58. Goldstein DJ, Wang O, Todd LE, et al. Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. *Clin Pharmacol Therapeut* 2000;67:419-426.

59. Scott DL, Berry H, Capell H, et al. The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. *Rheumatology* 2000;39:1095-1101.

60. Dickson DJ, Hosie G, English JR. A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. *J Drug Assess* 2001;4(Part 3):179-190.

61. Uzun H, Tuzun S, Ozaras N, et al. The effect of flurbiprofen and tiaprofenic acid on serum cytokine levels of patients with osteoarthrosis. *Acta Orthop Scand* 2001;72:499-502.

62. Kivitz A, Eisen G, Zhao WW, et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. *J Family Pract* 2002:530-537.

63. Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. *Arch Intern Med* 2003;163:169-178.

64. Gibofsky A, Williams GW, McKenna F, et al. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. *Arthritis Rheum* 2003;48:3102-3111.

65. Biegert C, Wagner I, Lüdtke R, et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials. *J Rheumat* 2004;31:2121-2130.

66. Schnitzer TJ, Beier J, Geusens P, et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2004;51:549-557.

67. Tannenbaum H, Berenbaum F, Reginster JY, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. *Ann Rheum Dis* 2004:1419-1426.

68. Haghighi M, Khalvat A, Toliat T, et al. Comparing the effects of ginger (Zingiber officinale) xtract and ibuprofen on patients with osteoarthritis. *Arch Iran Med* 2005;4:267-271.

69. Sheldon E, Beaulieu A, Paster Z, et al. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. *Clin Therapeut* 2005;27:64-77.

70. Tuzun S, Uzun H, Aydin S, et al. Effects of flurbiprofen and tiaprofenic acid on oxidative stress markers in osteoarthritis: A prospective, randomized, open-label, active- and placebo-controlled trial. *Curr Therapeut Res-Clin Experiment* 2005;66:335-344.

71. Svensson O, Malmenas M, Fajutrao L, et al. Greater reduction of knee than hip pain in osteoarthritis treated with naproxen, as evaluated by WOMAC and SF-36. *Ann Rheum Dis* 2006;65:781-784.

72. Dougados M, Moore A, Yu S, et al. Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. *Arthritis Res Therap* 2007;9:R11.

73. Kruger K, Klasser M, Mossinger J, et al. Oxaceprol--a randomised, placebo-controlled clinical study in osteoarthritis with a non-conventional non-steroidal anti-inflammatory drug. *Clin Exp Rheumatol* 2007;25:29-34.

74. Ding M-h, Zhang H, Li Y. A randomized controlled study on warming needle moxibustion for treatment of knee osteoarthritis. *Zhongguo zhenjiu* 2009;29:603-607.

75. DeLemos BP, Xiang J, Benson C, et al. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. *Am J Therapeut* 2011;18:216-226.

76. Petersen SG, Beyer N, Hansen M, et al. Nonsteroidal Anti-Inflammatory Drug or Glucosamine Reduced Pain and Improved Muscle Strength With Resistance Training in a Randomized Controlled Trial of Knee Osteoarthritis Patients. *Arch Phys Med Rehabil* 2011;92:1185-1193.

77. Schnitzer TJ, Hochberg MC, Marrero CE, et al. Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study. *Sem Arthritis Rheum* 2011;40:285-297.

FIGURE AND TABLE LEGENDS

Figure 1: Forest plot of mean change in pain score for NSAID versus Placebo for flare versus non-

flare trial design.

Figure 2: Forest plot of absolute pain score for NSAID versus Placebo for flare versus non-flare trial design.

Table 1: Flare versus non-flare trial design meta-analysis results by outcome measure.

Table 2: Flare versus non-flare trial design meta-analysis results as assessed by immediate, short- and longer-term follow-up intervals.

Table 3: Flare and possible flare versus non-flare trial design meta-analysis results as assessed by immediate, short, and longer-term follow-up intervals.

Table 4: Meta-regression of effect size of NSAIDs for osteoarthritis pain (number of observation=131)

Supplementary Figure 1: PRISMA flow-chart.

Supplementary Figure 2: Funnel plot assessing small sample size publication bias for primary outcome measure (mean change in pain score) for flare versus non-flare trial design.

Supplementary Table 1: MEDLINE search strategy

Supplementary Table 2: Study Characteristics (Study design)

Supplementary Table 3: Participant characteristics of the included studies (medications and demographics)

Supplementary Table 4: Summary of the included study quality assessment results

Figure 1: Forest plot of mean change in pain score for NSAID versus Placebo for flare versus non-flare trial design.

Study or Subgroup	Mean	NSAID SD	Total	Mean	acebo SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Std. Mean Difference IV, Random, 95% Cl
55.2.1 Flare Design									
Baerwald 2010	-25.81	30.8		-17.97	30.6	331	1.4%	-0.26 [-0.41, -0.10]	
Baerwald 2010	-24.31	27.9		-17.97	30.6	331	1.3%	-0.21 [-0.40, -0.02]	
Bensen 1999	-2.4	2.4	144	-1.3	2.4	146	1.3%	-0.46 [-0.69, -0.22]	
Bensen 1999	-2.3	2.4	143	-1.3	2.4	146	1.3%	-0.42 [-0.65, -0.18]	
Bensen 1999	-1.7	2.4	143	-1.3	2.4	146	1.3%	-0.17 [-0.40, 0.06]	
Bensen 1999	-2.2	2.4	144	-1.3	2.4	146	1.3%	-0.37 [-0.61, -0.14]	
Cryer 2011	3.17	9.14	245	3.73	9.23	123	1.3%	-0.06 [-0.28, 0.16]	
Cryer 2011	3.17	9.29	245	4.04	9.39	123	1.3%	-0.09 [-0.31, 0.12]	
Cryer 2011	-4.43	8.9	237	-3.72	9.23	123	1.3%	-0.08 [-0.30, 0.14]	
Day 2000	-23.37	18.3	244	-11.83	17.9	74	1.2%	-0.63 [-0.90, -0.37]	
Day 2000 Day 2000	-24.78 -22.89	18.6 18.6	242 249	-11.83 -11.83	17.9 17.9	74 75	1.2% 1.2%	-0.70 [-0.97, -0.43]	
Ehrich 1999	-22.09	24.8	73		20.44	72	1.1%	-0.60 [-0.86, -0.34]	
Ehrich 1999		18.17	73		20.44	72	1.1%	-0.92 [-1.26, -0.58] -1.08 [-1.43, -0.73]	
Ehrich 2001	-17.47	19.5	135	-6.16	19.5	134	1.3%	-0.58 [-0.82, -0.33]	
Ehrich 2001	-17.13	19.5	131	-6.16	19.5	134	1.3%	-0.56 [-0.81, -0.32]	
Ehrich 2001	-14.52	19.5	139	-6.16	19.5	134	1.3%	-0.43 [-0.67, -0.19]	
Ehrich 2001	-22.9	19.4	92	-6.16	19.5	134	1.2%	-0.86 [-1.13, -0.58]	
Essex 2012	-4.9	4.5	124	-4.7	4.8	65	1.2%	-0.04 [-0.34, 0.26]	
Essex 2012	-5.7	4.5	125	-4.7	4.8	65	1.2%	-0.22 [-0.52, 0.08]	
Fleischmann 2005	-3.7	4.14	463	-2.3	3.9	231	1.4%	-0.34 [-0.50, -0.19]	
Fleischmann 2005	-3.1	3.8	463	-1.6	3.1	231	1.4%	-0.42 [-0.58, -0.26]	
Fleischmann 2005	-2.9	3.63	444	-1.6	3.1	231	1.4%	-0.38 [-0.54, -0.22]	
Fleischmann 2005	-3.1	3.67	462	-1.6	3.1	231	1.4%	-0.43 [-0.59, -0.27]	——
Fleischmann 2005	-3.7	4.14	462	-2.3	3.9	231	1.4%	-0.34 [-0.50, -0.19]	——
Grifka 2004	-21.1	21.9	193	-12.5	16.8	196	1.3%	-0.44 [-0.64, -0.24]	
Grifka 2004	-21.3	19.2	205	-12.5	16.8	196	1.3%	-0.49 [-0.68, -0.29]	
Karlsson 2009	-37	22.04	109		22.17	79	1.2%	-0.74 [-1.04, -0.44]	
Karlsson 2009	-33.6	20.31	114		22.17	79	1.2%	-0.62 [-0.91, -0.33]	
Karlsson 2009	-33.3	21.74	118		22.17	79	1.2%	-0.58 [-0.87, -0.29]	
Karlsson 2009	-28.5	22.49	102		22.17	79	1.2%	-0.36 [-0.65, -0.06]	<u> </u>
Leung 2002	-25.76	20.4		-15.33	17.7	44	1.1%	-0.52 [-0.85, -0.19]	
Leung 2002	-25.32	19.3		-15.33	17.7	44	1.1%	-0.52 [-0.86, -0.19]	
McKenna 2001a McKenna 2001a	-3.5	2.81	199	-2.3	2.8	199	1.3%	-0.43 [-0.63, -0.23]	
McKenna 2001a	-3.4	2.7	199	-2	2.55	199	1.3%	-0.53 [-0.73, -0.33]	
Puopolo 2007	-24.1	22.8		-16.47	21.5	109	1.3%	-0.34 [-0.57, -0.11]	
Puopolo 2007	-28.14	23.3		-16.47	21.5	109	1.3%	-0.51 [-0.75, -0.28]	
Reginster 2007	-27.94	22.5		-15.31	21	112	1.3%	-0.57 [-0.78, -0.36]	
Reginster 2007	-28.57	22.5		-15.31	21	112	1.3%	-0.60 [-0.81, -0.39]	
Rother 2007 Schnitzer 2011b	-2.1 -31.3	2.27 25.9	132 241	-1.2 -20.4	2.08 25.9	117 256	1.2% 1.4%	-0.41 [-0.66, -0.16] -0.42 [-0.60, -0.24]	
	-31.3	25.9	241	-20.4	25.9	256	1.4%		
Schnitzer 2011b Schnitzer 2011b	-29.5	25.8	254	-20.4	25.9	256	1.4%	-0.30 [-0.47, -0.12] -0.35 [-0.53, -0.18]	
Wiesenhutter 2005		24.9	210	-20.4	23.4	104	1.3%	-0.42 [-0.65, -0.18]	
					20.4				
	-30.48 -30.92				23.4	104	1.3%	-0.44 (-0.67 -0.20)	
Wiesenhutter 2005	-30.48 -30.92 -4	24.9 24.6 3.3	214 145	-20.3 -2.7	23.4 3.2	104 75	1.3% 1.2%	-0.44 [-0.67, -0.20] -0.40 [-0.68, -0.12]	
	-30.92 -4 -4.4	24.6 3.3 4.4	214 145 114 10201	-20.3 -2.7 -2.7	3.2 3.2	75 75 <mark>6682</mark>	1.2% 1.2% 59.4%	-0.44 [-0.67, -0.20] -0.40 [-0.68, -0.12] -0.43 [-0.72, -0.13] -0.43 [-0.48, -0.38]	•
Wiesenhutter 2005 Wittenberg 2006 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 55.2.2 Non-Flare Des	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign	24.6 3.3 4.4 ii ^z = 113. 2 (P < 0.1	214 145 114 10201 16, df = 00001)	-20.3 -2.7 -2.7 46 (P < 0	3.2 3.2 .00001	75 75 6682); I ^z = 59 ⁰	1.2% 1.2% 59.4% %	-0.40 [-0.68, -0.12] -0.43 [-0.72, -0.13] -0.43 [-0.48, -0.38]	•
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 55.2.2 Non-Flare Des Biegert 2004	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23	24.6 3.3 4.4 ii [≈] = 113. 2 (P < 0.1 20	214 145 114 10201 16, df= 00001) 43	-20.3 -2.7 -2.7 46 (P < 0 -5	3.2 3.2 .00001	75 75 6682); I [≠] = 59° 41	1.2% 1.2% 59.4% %	-0.40 [-0.68, -0.12] -0.43 [-0.72, -0.13] -0.43 [-0.48, -0.38] -0.83 [-1.28, -0.38]	•
Wiesenhutter 2005 Wittenberg 2006 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ²¹ Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9	24.6 3.3 4.4 ii ² = 113. 2 (P < 0.1 20 79.3	214 145 114 10201 16, df = 00001) 43 25	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3	3.2 3.2 .00001 23 98.7	75 75 6682); I [≠] = 59 ⁴ 41 28	1.2% 1.2% 59.4% %	-0.40 [-0.68, -0.12] -0.43 [-0.72, -0.13] -0.43 [-0.48, -0.38] -0.83 [-1.28, -0.38] -0.42 [-0.97, 0.12]	•
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 Case 2003	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2	24.6 3.3 4.4 ii ² = 113. 2 (P < 0.1 20 79.3 68.2	214 145 114 10201 16, df = 00001) 43 25 25	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5	3.2 3.2 .00001 23 98.7 52.3	75 75 6682); I ² = 59° 41 28 28	1.2% 1.2% 59.4% % 0.9% 0.8% 0.8%	-0.40 [-0.68, -0.12] -0.43 [-0.72, -0.13] -0.43 [-0.48, -0.38] -0.43 [-1.28, -0.38] -0.42 [-0.97, 0.12] -0.96 [-1.53, -0.39]	• •
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 Cease 2003 DeLemos 2011	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -13	24.6 3.3 4.4 ii ² = 113. 2 (P < 0.1 20 79.3 68.2 12.82	214 145 114 10201 16, df = 00001) 43 25 25 203	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -9.49	3.2 3.2 .00001 23 98.7 52.3 12.59	75 75 6682); I [≠] = 59° 41 28 28 200	1.2% 1.2% 59.4% % 0.9% 0.8% 0.8% 1.3%	-0.40 [-0.68,-0.12] -0.43 [-0.72,-0.13] -0.43 [-0.748,-0.38] -0.43 [-0.48,-0.38] -0.42 [-0.97,0.12] -0.96 [-1.53,-0.39] -0.28 [-0.47,-0.08]	•
Wiesenhutter 2005 Wittenberg 2006 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 Case 2003 DeLemos 2011 Dickson 2001	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -23	24.6 3.3 4.4 i [#] = 113 2 (P < 0.1 20 79.3 68.2 12.82 31.2	214 145 114 10201 16, df= 00001) 43 25 25 203 55	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -9.49 -24	3.2 3.2 .000001 98.7 52.3 12.59 22.65	75 75 6682 0; I [≠] = 59 ⁴ 41 28 28 200 57	1.2% 1.2% 59.4% % 0.9% 0.8% 0.8% 1.3% 1.1%	-0.40 [-0.68, -0.12] -0.43 [-0.72, -0.13] -0.43 [-0.48, -0.38] -0.43 [-1.28, -0.38] -0.42 [-0.97, 0.12] -0.96 [-1.53, -0.39] -0.28 [-0.47, -0.08] 0.04 [-0.33, 0.41]	• •
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -60.2 -13 -23 -23 -254	24.6 3.3 4.4 i ² = 113 2 (P < 0.1 20 79.3 68.2 12.82 31.2 2.503	214 145 114 10201 16, df= 00001) 43 25 25 203 55 813	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -1.5 -24 : -1.98 :	3.2 3.2 .000001 98.7 52.3 12.59 22.65 2.475	75 75 6682 0; I [≠] = 59° 41 28 28 28 200 57 806	1.2% 1.2% 59.4% % 0.9% 0.8% 0.8% 1.3% 1.1% 1.4%	-0.40 [-0.68, -0.12] -0.43 [-0.72, -0.13] -0.43 [-0.748, -0.38] -0.43 [-0.48, -0.38] -0.42 [-0.97, 0.12] -0.96 [-1.53, -0.39] -0.28 [-0.47, -0.08] -0.28 [-0.47, -0.08] -0.24 [-0.33, 0.41] -0.22 [-0.32, -0.13]	•
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 Cease 2003 DeLemos 2011 Dickson 2001 Dougados 2007	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -23 -23 -23 -254 -2.02	24.6 3.3 4.4 i [™] = 113: 2 (P < 0.1 20 79.3 68.2 12.82 31.2 2.503 2.186	214 145 114 10201 16, df= 00001) 43 25 26 203 55 813 813	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -9.49 -24 : -1.98 : -1.21	3.2 3.2 .000001 98.7 52.3 12.59 22.65 2.475 1.992	75 75 6682); * = 59' 41 28 28 28 200 57 806 806	1.2% 1.2% 59.4% % 0.9% 0.8% 0.8% 1.3% 1.1% 1.4%	-0.40 [-0.68,-0.12] -0.43 [-0.72,-0.13] -0.43 [-0.748,-0.38] -0.43 [-0.48,-0.38] -0.42 [-0.37,0.12] -0.96 [-1.53,-0.39] -0.28 [-0.47,-0.08] 0.04 [-0.33,0.41] -0.22 [-0.32,-0.13] -0.39 [-0.49,-0.29]	•
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -60.2 -13 -23 -23 -254	24.6 3.3 4.4 i ² = 113 2 (P < 0.1 20 79.3 68.2 12.82 31.2 2.503	214 145 114 10201 16, df= 00001) 43 25 25 203 55 813	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -9.49 -24 : -1.98 : -1.21	3.2 3.2 .000001 98.7 52.3 12.59 22.65 2.475	75 75 6682 0; I [≠] = 59° 41 28 28 28 200 57 806	1.2% 1.2% 59.4% % 0.9% 0.8% 0.8% 1.3% 1.1% 1.4%	$\begin{array}{c} -0.40 \ [0.68 \ -0.12] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.748 \ -0.38] \\ -0.43 \ [-0.48 \ -0.38] \\ -0.42 \ [-0.97 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.33 \ (-0.43 \ -0.21] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ -0.48 \ -0.48 \ -0.48] \\ -0.48 \ -$	• •
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -23 -2.54 -2.02 -2.01	24.6 3.3 4.4 i [#] = 113. 2 (P < 0.1 20 79.3 68.2 12.82 31.2 2.503 2.186 2.197	214 145 114 10201 16, df = 000001) 43 25 26 203 55 203 55 813 813 813 811	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -9.49 -24 : -1.98 : -1.21	3.2 3.2 .000001 98.7 52.3 12.59 22.65 2.475 1.992 1.992	75 75 6682); * = 59' 41 28 28 200 57 806 806 806	1.2% 1.2% 59.4% % 0.9% 0.8% 0.8% 1.3% 1.4% 1.4%	-0.40 [-0.68,-0.12] -0.43 [-0.72,-0.13] -0.43 [-0.748,-0.38] -0.43 [-0.48,-0.38] -0.42 [-0.37,0.12] -0.96 [-1.53,-0.39] -0.28 [-0.47,-0.08] 0.04 [-0.33,0.41] -0.22 [-0.32,-0.13] -0.39 [-0.49,-0.29]	•
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -23 -2.54 -2.02 -2.01 -2.01	24.6 3.3 4.4 ji ² = 113 2 (P < 0.1 20 79.3 68.2 12.82 31.2 2.503 2.186 2.197 2.483	214 145 114 10201 16, df = 000001) 43 25 26 203 55 203 55 813 813 811 811	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -9.49 -24 : -1.98 : -1.21 -1.21 -1.28	3.2 3.2 .00001 98.7 52.3 12.59 22.65 2.475 1.992 1.992 2.475	75 75 6682); * = 59' 41 28 28 200 57 806 806 806 806	1.2% 1.2% 59.4% % 0.9% 0.8% 0.8% 1.3% 1.1% 1.4% 1.4%	$\begin{array}{c} -0.40 \ [-0.68 \ -0.12] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.48 \ -0.38] \\ -0.42 \ [-0.97 \ -0.12] \\ -0.96 \ [-153 \ -0.38] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.32 \ -0.13] \\ -0.39 \ [-0.48 \ -0.29] \\ -0.39 \ [-0.48 \ -0.28] \\ -0.28 \ [-0.48 \ -0.28] \\ -0.28 \ [-0.48 \ -0.28] \\ -0.28 \ [-0.48 \ -0.28] \\ -0.28 \ [-0.48 \ -0.28] \\ -0.28 \ [-0.58 \ -0.56] \\ -0.55 \ [-0.55 \ -0.56] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneiky: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Meñairy 1974	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -23 -2.54 -2.02 -2.01 -2.6 -1.7	24.6 3.3 4.4 i ^a = 113 2 (P < 0.1 20 79.3 68.2 12.82 31.2 2.503 2.186 2.197 2.483 0.3	214 145 114 10201 106, df = 00001) 43 25 26 203 55 813 813 813 811 811 20	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -9.49 -1.21 -1.21 -1.21 -1.21 -1.21 -1.28	3.2 3.2 .00001 98.7 52.3 12.59 22.65 2.475 1.992 1.992 2.475 0.1	75 75 6682); * = 59 41 28 20 20 57 806 806 806 806 806 806 17	1.2% 1.2% 59.4% % 0.9% 0.8% 1.3% 1.1% 1.4% 1.4% 1.4% 1.4% 0.2%	$\begin{array}{c} -0.40 \ [-0.68 \ -0.12] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.48 \ -0.38] \\ -0.42 \ [-0.97 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.42 \ [-0.97 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.28 \ [-0.47 \ -0.09] \\ 0.04 \ [-0.33 \ -0.47 \ -0.09] \\ 0.04 \ [-0.33 \ -0.47 \ -0.09] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.25 \ [-0.35 \ -0.15] \\ -5.88 \ [-7.44 \ -4.43] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -60.2 -13 -254 -2.02 -2.01 -2.6 -1.7 -1.33	24.6 3.3 4.4 ii [#] = 113 2 (P < 0.1 20 79.3 68.2 12.82 31.2 2.503 2.186 2.197 2.483 0.3	214 145 114 10201 16, df= 000001) 43 25 26 203 55 813 813 813 811 811 811 20 20 42	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -9.49 -24 : -1.98 : -1.21 -1.21 -1.21 -1.21 -1.21 -1.21 -1.21 -3.1 -0.35	3.2 3.2 .00001 98.7 52.3 12.59 22.65 2.475 1.992 2.475 0.1 0.1	75 75 6682); ² = 59' 41 28 20 20 57 806 806 806 806 806 17 17	1.2% 1.2% 59.4% % 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 0.2% 0.2%	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.48, -0.38] \\ -0.42 \ [-0.97, 0.12] \\ -0.96 \ [-1.63, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.25 \ [-0.36, -0.15] \\ -5.88 \ [-7, 44, -4.3] \\ -3.72 \ [-46, 22, -23] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -23 -254 -2.02 -2.04 -2.02 -2.04 -2.02 -2.05 -1.73 -1.33 -1.91	24.6 3.3 4.4 i ^{p=} = 113. 2 (P < 0.1 20 79.3 68.2 12.82 32.186 2.197 2.483 0.3 0.3 0.4	214 145 114 10201 116, df= 000001) 43 25 25 203 55 203 55 813 813 813 811 811 20 42 42	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -9.49 -1.98 : -1.98 : -1.21 -1.98 : -1.21 -1.98 : -0.31 -0.31	3.2 3.2 .000001 98.7 52.3 12.59 22.65 2.475 1.992 2.475 0.1 0.1 0.1 0.1	75 75 6682); l ² = 59' 41 28 28 200 57 806 806 806 806 806 17 17	1.2% 1.2% 59.4% % 0.9% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 0.4%	$\begin{array}{c} -0.40 [-0.68, -0.12] \\ -0.43 [-0.72, -0.13] \\ -0.43 [-0.72, -0.13] \\ -0.43 [-0.48, -0.38] \\ -0.42 [-0.97, -0.12] \\ -0.96 [-1.53, -0.39] \\ -0.42 [-0.97, -0.12] \\ -0.96 [-1.53, -0.39] \\ -0.28 [-0.47, -0.06] \\ -0.39 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.58 [-7.44, -4.33] \\ -3.72 [-4.62, -2.83] \\ -4.60 [-5.63, -3.57] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau"s Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -2.02 -2.01 -2.02 -2.01 -2.01 -2.02 -1.33 -1.33 -1.33 -1.71	24.6 3.3 4.4 i [#] = 113. 2 (P < 0.1 20 79.3 68.2 12.82 31.2 2.503 2.186 2.197 2.483 0.3 0.4 0.3 0.4 0.5	214 145 114 10201 16, df= 00001) 43 25 203 55 813 813 811 811 20 42 42 42 21	-20.3 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -9.49 -24 : -1.98 : -1.21 -1.21 -1.21 -1.98 : -0.31	3.2 3.2 .000001 98.7 52.3 12.59 22.65 2.475 1.992 2.475 1.992 2.475 0.1 0.1 0.1 0.1	75 6682); * = 59' 41 28 200 57 806 806 806 806 806 17 17 17 17	1.2% 1.2% 59.4% % 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 0.2% 0.4% 0.3%	$\begin{array}{c} -0.40 \ [-0.68 \ -0.12] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.42 \ [-0.37 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.42 \ [-0.37 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.03] \\ -0.28 \ [-0.47 \ -0.03] \\ -0.38 \ [-0.47 \ -0.03] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.25 \ [-0.55 \ -0.13] \\ -5.88 \ [-7.44 \ +4.33] \\ -3.72 \ [+4.62 \ -2.83] \\ -4.60 \ [+6.63 \ -3.57] \\ -3.62 \ [+4.69 \ -2.55] \\ -2.96 \ [+3.39 \ -2.00] \\ -2.04 \ [+2.85 \ -1.24] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity. Tau?= Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Del-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -80.2 -13 -2.54 -2.01 -2.01 -2.64 -2.02 -2.01 -2.64 -1.77 -1.33 -1.91 -1.71 -1.71 -1.71 -1.74 -1.44 -4.66	24.6 3.3 4.4 j ² = 113 2 (P < 0.1 20 79.3 68.2 12.82 31.2 2.503 2.186 2.197 2.483 0.3 0.4 0.3 0.4 0.5 0.5 0.5 4.1	214 145 114 10201 16, df = 000001) 43 25 25 203 55 813 813 811 20 42 42 21 20 21 20 21 190	-20.3 -2.7 -2.7 -2.7 -2.7 -2.7 -1.6.3 -1.5.3 -1.5.3 -1.5.3 -1.21 -24 -1.21 -1.21 -1.21 -1.21 -1.21 -0.31 -0.35 -0.35 -0.35 -0.35 -2.6	3.2 3.2 .000001 98.7 52.3 12.59 22.475 1.992 2.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 3.9	76 75 6682); ² = 59° 41 28 200 57 806 806 806 806 806 17 17 17 17 17 96	1.2% 1.2% 59.4% 59.4% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 0.2% 0.2% 0.4% 0.3% 0.3% 0.4% 0.3%	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.48, -0.38] \\ -0.42 \ [-0.97, 0.12] \\ -0.96 \ [-1.63, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.48, -0.29] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.3] \\ -3.72 \ [-4.62, -2.83] \\ -3.62 \ [-4.69, -2.56] \\ -3.62 \ [-4.69, -2.56] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.49 \ [-0.74, -0.24] \\ -0.49 \ [-0.74, -0.24] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974 El-Mehairy 1974	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -2.54 -2.02 -2.02 -2.66 -1.7 -2.66 -1.7 -1.33 -1.91 -1.71 -1.05 -1.14 -4.6 -4.7	24.6 3.3 4.4 i [#] = 113 2 (P < 0.1 79.3 68.2 12.82 31.2 2.503 2.186 2.197 2.483 0.3 0.4 0.5 0.3 0.4 0.5 0.3 0.4 1.4,1	214 145 114 10201 16, df = 000001) 43 25 203 55 203 55 813 813 811 811 811 811 20 42 42 42 21 120 20 21 189	$\begin{array}{c} -20.3 \\ -2.7 \\ -2.7 \\ 46 \ (P \leq 0 \\ \\ \\ -5 \\ -15.3 \\ -1.5 \\ -9.49 \\ -24 \\ -1.21 \\ -1.98 \\ -1.21 \\ -1.21 \\ -1.21 \\ -3.15 \\ -0.31 \\ -0.35 \\ -0.31 \\ -0.31 \\ -0.35 \\ -0.36 \\ -2.6 \end{array}$	3.2 3.2 3.2 .00001 98.7 52.3 12.59 22.65 2.475 1.992 2.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 9 3.9	75 6682 75 41 28 200 57 806 806 806 806 177 17 17 17 17 96	1.2% 59.4% 59.4% % 0.9% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.3% 1.3%	$\begin{array}{c} -0.40 \ [-0.68 \ -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.48, -0.38] \\ \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.53, -0.39] \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.53, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.42, -0.23] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.48 \ [-0.53, -0.52] \\ -2.06 \ [-0.52 \ [-0.77, -0.27] \\ -0.52 \ [-0.77, -0.27] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau? Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2011 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dickson 2017 Dougados 2007 Dickson 2017 Dougados 2007 Dickson 2017 Dougados 2007 Dickson 2017 Dickson 2017 Dougados 2007 Dickson 2017 Dickson 2017	-30.92 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -60.2 -13 -254 -2.54 -2.64 -1.7 -1.33 -1.91 -1.71 -1.71 -1.71 -1.71 -1.14 -4.6 -4.7 -24.1	24.6 3.3 4.4 i [≠] = 113. 2 (P < 0.1 20 79.3 68.2 12.82 31.2 2.503 2.186 2.197 2.483 0.3 0.4 0.5 4.1 26.1	214 145 114 10201 16, df = 000001) 43 25 203 55 813 813 811 811 20 42 21 20 21 190 189 134	-20.3 -2.7 -2.7 46 (P < 0 -5 -16.3 -1.5 -9.49 -24 -1.21 -1.21 -1.21 -1.21 -1.21 -1.21 -1.21 -0.31 -0.35 -0.35 -0.35 -0.35 -0.35 -2.6 -2.6 -2.6 -2.6 -18	3.2 3.2 3.2 000001, 98.7 52.3 12.59 22.65 2.475 1.992 2.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 3.9 2.55	76 6682); * = 59' 41 28 28 200 806 806 806 806 806 806 177 17 17 17 17 17 17 17 37	1.2% 59.4% 59.4% % % 0.9% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 0.2% 0.4% 0.4% 0.3% 0.4% 0.3% 0.5% 1.3% 1.3%	$\begin{array}{c} -0.40 \ [-0.68 - 0.12] \\ -0.43 \ [-0.72 - 0.13] \\ -0.43 \ [-0.72 - 0.13] \\ -0.43 \ [-0.74 - 0.38] \\ \hline \\ -0.42 \ [-0.97 , 0.12] \\ -0.96 \ [-1.53 - 0.39] \\ -0.42 \ [-0.97 , 0.12] \\ -0.96 \ [-1.53 - 0.39] \\ -0.28 \ [-0.47 - 0.08] \\ 0.04 \ [-0.32 , 0.13] \\ -0.22 \ [-0.32 , 0.13] \\ -0.28 \ [-0.47 - 0.09] \\ -0.38 \ [-0.47 - 0.02] \\ -0.38 \ [-0.47 - 0.02] \\ -0.38 \ [-0.47 - 0.02] \\ -0.38 \ [-0.47 - 0.02] \\ -0.38 \ [-0.47 - 0.02] \\ -0.38 \ [-0.47 - 0.02] \\ -0.38 \ [-0.48 - 0.28] \\ -0.26 \ [-0.35 - 0.15] \\ -0.26 \ [-0.55 - 0.12] \\ -0.26 \ [-0.55 - 0.29] \\ -0.52 \ [-0.57 - 0.24 \ [-0.47 - 0.02] \\ -0.52 \ [-0.57 - 0.02] \\ -0.52 \ [-0.57 - 0.02] \\ -0.52 \ [-0.57 - 0.02] \\ -0.52 \ [-0.57 - 0.02] \\ -0.52 \ [-0.57 - 0.02] \\ -0.52 \ [-0.57 - 0.02] \\ -0.52 \ [-0.57 - 0.02] \\ -0.52 \ [-0.57 - 0.02] \\ -0.52 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.02] \\ -0.57 \ [-0.57 - 0.0$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau?= Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -2.01 -2.04 -2.04 -2.01 -2.64 -2.02 -2.01 -2.64 -1.77 -1.33 -1.91 -1.71 -1.91 -1.71 -1.95 -1.14 -4.6 -4.7 -2.21	24.6 3.3 4.4 i ^p = 113 2 (P < 0.1 20 79.3 68.2 12.82 31.2 2.503 2.186 2.197 2.483 0.3 0.3 0.3 0.3 0.3 0.5 0.3 0.5 0.3 0.5 4.1 4.1 4.4 1.2 4.7 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	214 145 114 10201 116, df= 000001) 43 25 203 55 203 55 203 55 813 811 811 811 20 42 42 42 21 20 21 190 189 134 140	$\begin{array}{c} -20.3 \\ -2.7 \\ -2.7 \\ 46 \ (P < 0 \\ \\ \\ -5 \\ -15.3 \\ -1.5 \\ -9.49 \\ -1.21 \\ -1.98 \\ \\ -1.21 \\ -1.98 \\ \\ -1.21 \\ -1.98 \\ -1.21 \\ -0.35 \\ -0.35 \\ -0.31 \\ -0.31 \\ -0.31 \\ -0.35 \\ -0.35 \\ -2.6 \\ -2.6 \\ -18 \\ -18 \end{array}$	3.2 3.2 3.2 .000001 223 98.7 52.3 22.475 0.1 1.992 2.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	76 6682); * = 59' 41 28 28 200 57 806 806 806 806 806 806 806 806 17 17 17 17 17 17 17 17 17 17 17	1.2% 59.4% 59.4% 8% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 0.4% 0.4% 0.4% 0.3% 0.4% 0.3% 0.4% 0.3% 1.3% 1.3%	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.48, -0.38] \\ \hline \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.53, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.32, -0.13] \\ -0.39 \ [-0.49, -0.29] \\ -0.38 \ [-0.49, -0.29] \\ -0.38 \ [-0.49, -0.29] \\ -0.38 \ [-0.49, -0.29] \\ -0.38 \ [-0.48, -0.28] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.33] \\ -3.72 \ [-4.62, -2.83] \\ -4.60 \ [-5.63, -3.57] \\ -3.62 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.49 \ [-0.74, -0.25] \\ -0.52 \ [-0.74, -0.27] \\ -0.24 \ [-0.47, -0.02] \\ -0.29 \ [-0.52, -0.05] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneiky: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974 El	-30.92 -4.4 = 0.02; Ch : Z = 16.3: sign -23 -53.9 -60.2 -13 -23 -54 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -1.77 -1.13 -1.14 -1.05 -1.14 -4.6 -4.7 -24.1 -25.2 -4.23	24.6 3.3 4.4 i [#] = 113.2 2 (P < 0.1 20 79.3 12.82 31.2 2.503 2.186 2.197 2.483 0.3 0.4 0.5 4.1 26.1 24.1 26.1 24.1 26.1 24.1 26.1 24.1 26.1 24.1 26.1 26.1 26.1 26.1 26.1 26.1 26.1 26.1 27.1 26.1 27.1	214 145 114 100001 16, df= 00001) 43 25 25 203 55 813 813 811 20 42 20 42 42 21 20 21 190 21 199 134 140	-20.3 -2.7 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -9.49 -2.4 -1.98 -1.21 -1.21 -1.21 -1.21 -1.21 -1.21 -0.31 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -2.6 -18 -2.6 -18 -2.6 -18 -2.7 -2.7 -2.7 -2.7 -2.7 -2.7 -2.7 -2.7	3.2 3.2 3.2 0.00001 23 98.7 52.3 12.59 22.65 52.3 1.992 2.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	76 6682); * = 59 41 28 28 200 57 806 806 806 806 806 806 806 177 17 17 17 17 17 17 17 17 17 89 89	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 0.2% 0.4% 0.3% 0.4% 0.3% 1.3% 1.3% 1.3% 1.3%	$\begin{array}{c} -0.40 [-0.68, -0.12] \\ -0.43 [-0.72, -0.13] \\ -0.43 [-0.72, -0.13] \\ -0.43 [-0.48, -0.38] \\ \hline \\ -0.42 [-0.97, -0.12] \\ -0.96 [-1.53, -0.39] \\ -0.42 [-0.97, -0.12] \\ -0.96 [-1.53, -0.39] \\ -0.28 [-0.47, -0.06] \\ -0.28 [-0.32, -0.13] \\ -0.39 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.38 [-0.49, -0.29] \\ -0.52 [-0.55, -0.15] \\ -2.96 [-3.93, -2.00] \\ -2.04 [-2.85, -1.24] \\ -0.49 [-0.74, -0.25] \\ -0.52 [-0.77, -0.27] \\ -0.24 [-0.47, -0.06] \\ -0.29 [-0.52, -0.05] \\ -2.46 [-2.81, -2.06] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974 El-Meh	-30.92 -4.4 = 0.02; ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -2.54 -2.01 -2.64 -2.01 -2.65 -1.7 -1.33 -1.91 -1.71 -1.05 -1.14 -4.66 -4.7 -24.1 -25.2 -2.43 3.79	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ \mathbf{P}=113\\ 2\ (\mathbf{P}<0.\\ \mathbf{P}=30\\ \mathbf{P}<0\\ \mathbf{P}=30\\ P$	214 4 145 141 110 110 df = 000001) 116, df = 000001) 116, df = 000001) 116, df = 000001 118 110 118 110 118 100	$\begin{array}{c} -20.3 \\ -2.7 \\ -2.7 \\ 46 \ (P < 0 \\ \\ \\ -56 \\ -15.3 \\ -1.5 \\ -1.5 \\ -1.24 \\ -1.98 \\ -24 \\ -1.98 \\ -1.21 \\ -1.98 \\ -1.21 \\ -1.98 \\ -1.21 \\ -1.98 \\ -0.35 \\ -0.35 \\ -0.35 \\ -0.35 \\ -0.35 \\ -0.35 \\ -0.35 \\ -0.35 \\ -0.35 \\ -0.35 \\ -2.6 \\ -2.6 \\ -1.6 \\ -1.8 \\ -1.8 \\ -0.79 \\ 0.79 \\ \end{array}$	3.2 3.2 3.2 000001 23 98.7 12.59 22.65 2.475 1.992 2.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	75 6682); ² = 59' 41 28 28 200 57 806 806 806 806 806 17 17 17 17 17 17 17 17 17 17 17 17 17	1.2% 1.2% 59.4% 59.4% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 0.4% 0.4% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 1.3% 1.3% 1.3%	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.48, -0.38] \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.63, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.25 \ [-0.33, -0.41] \\ -0.25 \ [-0.33, -0.15] \\ -5.88 \ [-7.44, -4.33] \\ -3.72 \ [-4.62, -2.83] \\ -3.62 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.96 \ [-3.93, -2.00] \\ -2.96 \ [-3.93, -2.00] \\ -2.96 \ [-3.93, -2.00] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-0.47, -0.02] \\ -0.29 \ [-0.47, -0.02] \\ -0.29 \ [-0.47, -0.06] \\ -0.29 \ [-0.52, -0.05] \\ -2.45 \ [-2.81, -2.08] \\ -1.83 \ [1.50, 2, -71] \\ -1.83 \ [1.50, 2, -71] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974 El-	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.3: sign -23 -53.9 -60.2 -0.01 -2.0 -2.01 -2.01 -2.04 -2.01 -2.04 -2.01 -2.05 -1.7 -1.33 -1.91 -1.7 -1.14 -4.6 -4.7 -2.4,23 -2.54 -4.23 -3.79 -0.92 -1.04 -2.03 -2.04 -2.04 -2.05 -2.04 -2.04 -2.05 -2.04 -2.05 -2.0	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ 1^{2}=113\\ 2(P<0.\\ 79.3\\ 68.2\\ 21.2\\ 21.2\\ 21.2\\ 21.2\\ 21.2\\ 21.2\\ 21.2\\ 31.2\\ 21.2\\ 31.2\\$	214 145 114 10000000000000000000000000000	$\begin{array}{c} -20.3 \\ -2.7 \\ 46 \ (P < 0 \\ \\ \\ -5 \\ -15.3 \\ -1.5 \\ -9.49 \\ -24 \\ -1.21 \\ -1.98 \\ -24 \\ -1.21 \\ -1.98 \\ -1.21 \\ -1.98 \\ -1.21 \\ -3.5 \\ -0.31 \\ -0.31 \\ -0.35 \\ -0.31 \\ -0.35 \\ -0.35 \\ -2.6 \\ -1.8 \\ -1.8 \\ -0.79 \\ 0.79 \\ 0.79 \\ 0.79 \\ -4.8 \end{array}$	3.2 3.2 3.2 0.00001 23 98.7 52.3 12.59 22.65 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	75 6682); * = 59' 41 28 200 57 806 806 806 806 806 17 17 17 17 17 17 17 17 17 17 17 17 17	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.3% 1.3% 1.3% 1.3%	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.48, -0.38] \\ \hline \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-153, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.48, -0.29] \\ -0.39 \ [-0.48, -0.29] \\ -0.39 \ [-0.48, -0.28] \\ -0.39 \ [-0.48, -0.28] \\ -0.39 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.48 \ [-0.53, -0.16] \\ -5.88 \ [-7.44, -4.33] \\ -3.72 \ [-4.62, -2.83] \\ -3.72 \ [-4.62, -2.83] \\ -3.72 \ [-4.62, -2.83] \\ -3.72 \ [-4.62, -2.83] \\ -3.72 \ [-6.63, -3.57] \\ -3.62 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -0.24 \ [-0.47, -0.02] \\ -0.52 \ [-0.77, -0.27] \\ -0.24 \ [-0.47, -0.00] \\ -0.24 \ [-0.47, -0.02] \\ -0.45 \ [-0.52, -1.06] \\ -2.46 \ [-2.81, -2.08] \\ -1.83 \ [1.50, 2.17] \\ -0.27 \ [-0.48, -0.06] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dickson 2001 Dougados 2007 Dickson 2001 Dougados 2007 Dickson 2001 Dougados 2007 Dickson 2001 Dougados 2007 Dickson 2001 Dickson 2001 Dickson 2001 Dickson 2003 Dickson 2003 El-Mehairy 1974 El-Mehairy	-30.92 -4.44 = 0.02; Ch : Z = 16.32 sign -23 -538 -60.2 -13 -254 -2.04 -2.04 -2.01 -2.65 -1.7 -1.33 -1.91 -1.71 -1.71 -1.71 -1.15 -1.14 -2.62 -1.77 -2.42 -3,379 -0.4 -2.62 -1.42 -1.42 -1.44 -1.42 -1.444 -1.44 -	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ 20\\ 0\\ 20\\ 79.3\\ 68.2\\ 2.12.82\\ 2.12.82\\ 2.12.82\\ 2.12.82\\ 2.137\\ 0.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 1.2.186\\ 0.3\\ 0.4\\ 1.2.186\\ 1.2.186\\ 0.5\\ 4.1\\ 1.2.18\\ 1.2.186\\ 1.2.1$	214 145 114 102011 116, df= 203 203 813 813 811 811 120 422 422 21 200 813 813 811 811 190 189 134 420 1190 189 134 140 139 134 140 139 130 140 145 145 114 114 114 114 114 114 114 114	-20.3 -2.7 -2.7 -2.7 46 (P < 0 -5 -15.3 -1.5 -3.49 -2.4 -1.98 -1.21 -1.98 -1.21 -1.98 -1.21 -1.98 -1.21 -1.98 -0.35 -0.31 -0.35 -0.31 -0.35 -0.3	3.2 3.2 3.2 0.00001 98.7 52.3 12.69 22.85 2.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 76682 28 806 806 806 806 806 806 806 806 806 80	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 0.8% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3	$\begin{array}{c} -0.40 \ [-0.68 - 0.12] \\ -0.43 \ [-0.72 , -0.13] \\ -0.43 \ [-0.72 , -0.13] \\ -0.43 \ [-0.72 , -0.13] \\ -0.42 \ [-0.37 , -0.12] \\ -0.96 \ [-1.53 , -0.39] \\ -0.42 \ [-0.37 , -0.12] \\ -0.96 \ [-1.53 , -0.39] \\ -0.28 \ [-0.47 , -0.08] \\ -0.28 \ [-0.47 , -0.08] \\ -0.28 \ [-0.47 , -0.08] \\ -0.28 \ [-0.47 , -0.29] \\ -0.38 \ [-0.48 , -0.29] \\ -0.38 \ [-0.48 , -0.29] \\ -0.38 \ [-0.48 , -0.29] \\ -0.25 \ [-0.55 , -0.15] \\ -5.68 \ [-7.44 , -4.33] \\ -3.72 \ [-4.62 , -2.83] \\ -4.60 \ [-6.63 , -3.57] \\ -3.62 \ [-4.69 , -2.55] \\ -2.96 \ [-3.39 , -2.00] \\ -2.04 \ [-2.65 , -1.24] \\ -0.49 \ [-0.77 , -0.27] \\ -0.24 \ [-0.47 , -0.06] \\ -0.52 \ [-0.52 , -0.05] \\ -2.45 \ [-2.81 , -2.00] \\ 1.83 \ [1.50 , 2.17] \\ -0.27 \ [-0.48 , -0.06] \\ -0.63 \ [-0.63 , -0.63] \\ -0.63 \ [-0.63 \ [-0.63] \\ -0.63 \ [-0.63 \ [-0.63] \\ -0.63 \ [-0.63 \ [-0.63] \\ -0.63 \ [-0.63 \ [-0.63] \\ -0.63 \ [-0.63 \ [-0.63] \\ -0.63 \ [-0.63 \ [-0.63 \ [-0.63] \\ -0.63 \ [-0.63 \ [-0.63] \\ -0.63 \ [-0.63 \ [-0.63] \\ -0.63 \ [-0.63 \ [-0.63] \\ -0.63 \ [-0.63 \ [-0.63 \ [-0.63] \\ -0.63 \ [-0.63 \ [-0.63 \ [-0.63 \ [-0.63] \\ -0.63 \ [-0$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity. Tau? Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Del-Mehairy 1974 El-Mehairy 1974 El-Me	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -2.54 -2.01 -2.61 -2.61 -2.62 -2.01 -2.63 -1.91 -1.71 -1.71 -1.71 -1.71 -1.75 -1.14 -4.66 -4.7 -24.11 -25.2 -4.23 3.799 -10.4 -21.88 -60.22 -1.88 -60.22 -1.88 -60.22 -1.84	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ 1^{2}=113\\ 2(P<0.\\ 79.3\\ 68.2\\ 12.82\\ 2.503\\ 31.2\\ 2.503\\ 2.186\\ 0.3\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5$	214 145 114 10201 116, df= 20001) 325 200 325 203 35 55 813 813 811 200 21 200 21 120 201 201 814 42 200 21 190 199 41 40 201 199 199 41 40 201 199 201 201 201 201 201 201 201 201 201 201	$\begin{array}{c} -20.3 \\ -2.7 \\ -2.7 \\ 46 \ (P < 0 \\ \\ \\ -5 \\ -15.3 \\ -1.5 \\ -3.49 \\ -1.21 \\ -1.98 \\ -1.21 \\ -1.98 \\ -1.21 \\ -1.98 \\ -1.21 \\ -1.98 \\ -1.21 \\ -0.35 \\ -0.$	3.2 3.2 3.2 0.00001 98.7 52.3 12.59 2.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 66622 (;) = 59' 41 28 200 57 806 806 806 806 806 806 806 806 17 7 17 17 17 17 17 17 17 137 137 137 1	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 0.2% 0.4% 0.2% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 1.3% 1.2%	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.74, -0.38] \\ \hline \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.53, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.28] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.33] \\ -3.72 \ [-4.62, -2.83] \\ -4.60 \ [-5.63, -3.57] \\ -3.62 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.49 \ [-0.74, -0.25] \\ -0.52 \ [-0.74, -0.25] \\ -0.52 \ [-0.74, -0.27] \\ -0.24 \ [-0.48, -0.06] \\ -1.83 \ [1.50, -2.17] \\ -0.27 \ [-0.48, -0.06] \\ -0.63 \ [-0.83, -0.22] \\ -0.50 \ [0.21, 0.79] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneiky: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dickson 2001 El-Mehairy 1974 El-Mehairy 19	-30.92 -4.44 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -23 -23 -2.3 -2.3 -2.23 -2.24 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -1.77 -1.133 -1.91 -1.14 -4.67 -2.42 -2.423 -3.78 -104 -2.18 -62 -3.66	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ \mu^{2}=113\\ 2(P<0.\\ 79.3\\ 68.2\\ 2.102\\ 31.2\\ 2.503\\ 31.2\\ 2.503\\ 31.2\\ 2.503\\ 31.2\\ 2.503\\ 31.2\\ 2.186\\ 2.197\\ 2.483\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.$	214 145 114 100001) 433 255 265 203 203 255 813 813 813 813 811 811 20 42 21 21 20 21 190 21 189 184 134 140 40 20 21 189 188 188 188 188 188 188 188 19 43 391	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ -2.7\\ \end{array}$	3.2 3.2 3.2 0.00001, 23 98.7 52.3 12.59 22.475 0.1 1.992 2.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 6682 (;) = 59' 41 28 200 57 806 806 806 806 806 806 17 17 17 17 17 17 17 17 13 7 89 89 89 89 89 89 89 89 89 89 80 172 137 17 137 17 17 137 17 17 17 17 17 17 17 17 17 17 17 17 17	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 0.2% 0.4% 0.2% 0.4% 0.3% 0.4% 0.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4% 1.3% 1.4% 1.4%	$\begin{array}{c} -0.40 \ [-0.68 \ -0.12] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.42 \ [-0.97 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.42 \ [-0.97 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.26 \ [-0.55 \ -0.15] \\ -5.88 \ [-7.44 \ -4.33] \\ -3.72 \ [-4.62 \ -2.83] \\ -3.62 \ [-4.62 \ -2.83] \\ -3.62 \ [-4.62 \ -2.83] \\ -3.62 \ [-4.62 \ -2.83] \\ -3.62 \ [-4.62 \ -2.83] \\ -3.62 \ [-4.62 \ -2.83] \\ -3.62 \ [-4.62 \ -2.83] \\ -3.62 \ [-4.62 \ -2.83] \\ -3.62 \ [-4.62 \ -2.83] \\ -3.62 \ [-4.62 \ -2.83] \\ -3.62 \ [-4.62 \ -2.83] \\ -3.62 \ [-4.62 \ -2.83] \\ -3.62 \ [-6.63 \ -2.45] \\ -2.45 \ [-2.81 \ -2.08] \\ -3.63 \ [-0.48 \ -0.06] \\ -0.63 \ [-0.48 \ -0.06] \\ -0.63 \ [-0.32 \ -0.48 \ -0.06] \\ -0.63 \ [-0.32 \ -0.48 \ -0.06] \\ -0.63 \ [-0.32 \ -0.48 \ -0.06] \\ -0.63 \ [-0.32 \ -0.48 \ -0.06] \\ -0.52 \ [-0.77 \ -0.27 \ [-0.48 \ -0.06] \\ -0.63 \ [-0.32 \ -0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.22 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.22 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.22 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.22 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.22 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.22 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ [-0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ -0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ -0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ -0.48 \ -0.64] \\ -0.52 \ [-0.79 \ -0.21 \ -0.48 \ -0.64] \\ -0.52 \ -0$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau? Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Diel-Mehairy 1974 El-Mehairy 1974 El-	-30.92 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -539 -60.2 -13 -2.54 -2.02 -2.01 -2.6 -1.7 -1.33 -1.91 -1.71 -1.05 -1.17 -1.05 -4.6 -4.7 -24.1 -25.2 -4.23 -3.79 -10.4 -21.8 -3.6 -3.6 -3.4	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ 1^{p}=113\\ 2(P<0.2\\ 12.8\\ 2.6\\ 12.8\\ 2.5\\ 12.8\\ 2.5\\ 12.8\\ 2.5\\ 12.8\\ 2.5\\ 12.8\\ 2.5\\ 12.8\\ 2.5\\ 12.8\\ 2.197\\ 2.483\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.$	214 145 114 10201 116, df= 200001) 433 25 25 203 5 26 203 5 20 203 5 20 203 5 20 20 20 20 20 20 20 20 20 20 20 20 20	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ 46 \ (P < 0\\ -5\\ -16.3\\ -1.5\\ -9.49\\ -24\\ -1.98\\ -24\\ -1.98\\ -1.21\\ -1.98\\ -1.21\\ -1.98\\ -1.21\\ -1.98\\ -0.35\\ -0.31\\ -0.31\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -2.6\\ -2$	3.2 3.2 3.2 98.7 52.3 98.7 52.3 22.65 22.65 22.475 1.992 24.75 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 6662 17 28 200 507 806 806 806 806 806 806 806 17 17 17 17 17 17 17 17 137 89 96 137 137 89 9172 137 2382 805 805 805 805 805 805 805 805 805 805	1.2% 59.4% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 0.2% 0.2% 0.2% 0.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.3% 1.3% 1.3% 1.1% 1.3% 1.2% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.2% 1.2% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.2% 1.2% 1.4% 1.2% 1.2% 1.4% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.4% 1.2% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4%	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.63, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.25 \ [-0.33, -0.14] \\ -0.39 \ [-0.48, -0.29] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.3] \\ -3.72 \ [-4.62, -2.83] \\ -3.62 \ [-4.69, -2.56] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.49 \ [-0.47, -0.02] \\ -0.29 \ [-0.52, -0.05] \\ -2.45 \ [-2.85, -1.24] \\ -0.49 \ [-0.47, -0.02] \\ -0.24 \ [-0.45, -0.06] \\ -0.63 \ [-0.43, -0.06] \\ -0.63 \ [-0.63, -0.42] \\ -0.50 \ [0.21, 0.79] \\ -0.32 \ [-0.41, -0.18] \\ -0.27 \ [-0.41, -0.18] \\ -0.27 \ [-0.41, -0.18] \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -2.01 -2.02 -2.01 -2.64 -2.02 -2.01 -2.65 -1.33 -2.54 -2.02 -2.01 -2.65 -1.14 -4.66 -4.7 -2.52 -4.23 3.799 -10.4 -2.52 -2.52 -2.54 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.75 -2.02 -2.01 -2.64 -2.77 -1.33 -2.54 -2.64 -2.77 -1.33 -2.54 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.65 -2.02 -2.01 -2.65 -2.02 -2.01 -2.65 -2.02 -2.01 -2.65 -2.02 -2.01 -2.65 -2.02 -2.01 -2.65 -2.02 -2.01 -2.65 -2.10 -2.77 -1.33 -2.54 -2.02 -2.01 -2.64 -2.77 -1.77 -1.77 -1.77 -1.77 -1.77 -2.72 -2.02 -2.01 -2.74 -2.75 -2.01 -2.75 -2.02 -2.01 -2.02 -2.01 -2.01 -2.02 -2.01 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -1.77 -1.73 -3.79 -2.02 -2.01 -2.02 -2.01 -1.77 -2.02 -2.02 -2.01 -1.77 -2.02 -2.02 -2.01 -2.02 -2.01 -2.02 -2.02 -2.01 -2.02 -2.02 -2.01 -2.02 -2	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ 1^{2}=113\\ 2(P<0.\\ 79.3\\ 68.2\\ 12.82\\ 2.503\\ 2.186\\ 0.3\\ 0.5\\ 2.197\\ 2.483\\ 0.3\\ 0.5\\ 0.3\\ 0.5\\ 0.3\\ 0.4\\ 0.3\\ 0.5\\ 0.3\\ 0.4\\ 1.4\\ 1.26.7\\ 1.4\\ 4.2\\ 2.77\\ 1.4\\ 20.7\\ 2.65\\ 5.40\\ 4.2\\ 2.42\\ 1.28\\ 20.7\\ 1.28\\ 20.7\\ 1.28\\ 20.7\\ 2.42\\ 2.42\\ 1.28\\ 20.7\\ 2.42\\ 2.4$	214 145 114 116, df= 200001) 325 203 25 203 25 203 25 203 325 203 313 813 813 813 813 813 813 811 20 21 21 20 21 21 20 189 134 42 20 21 20 19 20 19 20 19 20 20 20 20 20 20 20 20 20 20 20 20 20	$\begin{array}{c} -20.3 \\ -2.7 \\ 46 \ (P < 0 \\ \\ \\ -5 \\ -15.3 \\ -1.5 \\ -9.49 \\ -1.21 \\ \\ -1.98 \\ \\ -1.21 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -1.98 \\ \\ -2.4 \\ \\ -2.6 \\ \\ -2.6 \\ \\ -2.6 \\ \\ -1.8 \\ \\ -2.6 \\ \\ -2.$	3.2 3.2 3.2 0.00001, 23 98.7 52.3 22.65 24.75 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 66622 (;) F = 59' 41 28 200 57 806 806 806 806 806 806 806 806 17 7 17 17 17 17 17 17 17 17 17 17 13 7 13 7 13 7 13 7 17 5 382 382 382 382 382 175	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.74, -0.38] \\ \hline \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-153, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.32, -0.13] \\ -0.39 \ [-0.48, -0.29] \\ -0.39 \ [-0.48, -0.28] \\ -0.39 \ [-0.48, -0.28] \\ -0.39 \ [-0.48, -0.28] \\ -0.39 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.38 \ [-0.48, -0.28] \\ -0.48 \ [-0.23, -0.13] \\ -0.39 \ [-0.48, -0.28] \\ -0.48 \ [-0.53, -0.16] \\ -5.88 \ [-7.44, -4.33] \\ -3.72 \ [-4.62, -2.83] \\ -4.60 \ [-5.63, -3.57] \\ -3.62 \ [-4.62, -2.83] \\ -4.60 \ [-5.63, -3.57] \\ -3.62 \ [-4.62, -2.83] \\ -4.60 \ [-5.63, -3.57] \\ -0.52 \ [-0.77, -0.27] \\ -0.24 \ [-0.48, -0.06] \\ -0.63 \ [-0.83, -2.00] \\ -0.63 \ [-0.83, -0.42] \\ -0.50 \ [0.27, \ [-0.48, -0.18] \\ -0.27 \ [-0.48, -0.16] \\ -0.48 \ [-0.68, -0.31] \\ -0.27 \ [-0.48, -0.16] \\ -0.68 \ [-0.68, -0.31] \\ -0.27 \ [-0.48, -0.16] \\ -0.68 \ [-0.68, -0.31] \\ -0.49 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.68, -0.50] \\ -0.68 \ [-0.50] \\ -0.68 \ [-0.50] \\ -0.68 \ [-0.50] \\ -0.68 \ [-0.50] \\ -0.68 \ [-0.50] \\ -0.50 \ [-0.68, -0.50] \\ -0.50 \ [-0.68, -0.50] \\ -0.50 \ [-0.68, -0.50] \\ -0.50 \ [-0.68, -0.50] \\ -0.50 \ [-0.68, -0.50] \\ -0.50 \ [-0.68, -0.50] \\ -0.50 \ [-0.68, -0.50] \\ -0.50 \ [-0.68, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.58, -0.50] \\ -0.50 \ [-0.$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974 El-Mehai	-30.92 -4.44 = 0.02; Ch : Z = 16.32 sign -23 -53.8 -60.2 -13 -2.54 -2.04 -2.02 -2.01 -2.6 -1.7 -1.33 -1.91 -1.71 -1.71 -1.71 -1.71 -1.71 -1.71 -1.74 -4.63 -3.79 -0.4 -25.2 -3.79 -0.4 -21.88 -3.8 -3.4 -21.88 -3.4 -21.88 -3.4 -21.88 -3.4 -21.88 -3.4 -21.88 -3.4 -21.88 -3.48 -2.54 -2.52 -2.52 -2.52 -2.54 -2.52 -2.52 -2.54 -2.52 -2.54 -2.54 -2.52 -2.54 -2.	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ p^{2}=1113\\ 2(P<0.2\\ 0, 0\\ 200\\ 79.3\\ 68.2\\ 2.12, 82\\ 2.12, 82\\ 2.12, 82\\ 2.13, 32\\ 2.140\\ 3.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 1.4\\ 1.8\\ 20.7\\ 4.1\\ 1.4\\ 1.8\\ 20.7\\ 4.2\\ 1.5\\ 4.1\\ 24.7\\ 1.4\\ 1.8\\ 20.7\\ 4.2\\ 1.5\\ 1.5\\ 1.5\\ 1.5\\ 1.5\\ 1.5\\ 1.5\\ 1.5$	214 145 114 102011 116, df= 200001) 433 25 25 26 203 813 813 811 811 120 422 42 21 190 422 21 190 422 21 190 189 41 303 818 189 94 1393 2803	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ -2.7\\ 46 \ (P < 0\\ \\ \\ \\ \\ -5\\ -16.3\\ -1.5\\ -3.49\\ -1.21\\ \\ \\ -1.98\\ \\ \\ -1.21\\ \\ -1.98\\ \\ \\ -1.21\\ \\ -1.98\\ \\ -1.21\\ \\ -1.98\\ \\ -1.21\\ \\ -1.98\\ \\ -1.21\\ \\ -1.98\\ \\ -1.21\\ \\ -1.98\\ \\ -1.21\\ \\ -1.98\\ \\ -1.21\\ \\ -1.98\\ \\ -1.21\\ \\ -$	3.2 3.2 3.2 0.00001, 23 98.7 52.3 12.69 22.65 1.992 24.75 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 76682 1, * = 59' 41 28 28 200 57 806 806 806 806 806 806 806 806 806 17 17 17 17 17 137 137 137 137 137 137	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 0.8% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.5% 1.3% 1.5	$\begin{array}{c} -0.40 \ [-0.68 \ -0.12] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.42 \ [-0.87 \ -0.88] \\ -0.42 \ [-0.87 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.42 \ [-0.87 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.28] \\ -0.28 \ [-0.47 \ -0.28] \\ -0.28 \ [-0.47 \ -0.28] \\ -0.28 \ [-0.47 \ -0.28] \\ -0.28 \ [-0.47 \ -0.28] \\ -0.26 \ [-0.55 \ -0.26] \\ -5.88 \ [-7.44 \ -4.33] \\ -3.72 \ [-4.62 \ -2.55] \\ -2.96 \ [-3.93 \ -2.00] \\ -2.04 \ [-2.65 \ -1.24] \\ -0.49 \ [-0.77 \ -0.27] \\ -0.24 \ [-0.47 \ -0.26] \\ -0.63 \ [-0.83 \ -0.26] \\ -0.83 \ [-0.83 \ -0.48] \\ -0.27 \ [-0.48 \ -0.06] \\ -0.83 \ [-0.83 \ -0.48] \\ -0.27 \ [-0.46 \ -0.18] \\ -0.27 \ [-0.46 \ -0.13] \\ -0.49 \ [-0.86 \ -0.33] \\ -0.49 \ [-0.86 \ -0.33] \\ -0.49 \ [-0.86 \ -0.33] \\ -0.49 \ [-0.86 \ -0.30] \\ -0.45 \ [-0.83 \ -0.30] \\ -0.45 \ -0.30 \ -0.45 \ -0.30] \\ -0.45 \ -0.45 \ -0.30 \ -0.45 \ -0.30] \\ -0.45 \ -0.45 \ -0.45 \ -0.30] \\ -0.45 \ -0.45 \ -0.30 \ -0.45 $	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 2003 Gibofsky 2003 Cibofsky 2003 Elund 1998 Lund 1998 Paul 2009 Pincus 2004a Schnitzer 2004 Sheldon 2005 Syensson 2006h Svensson 2006h	-30.92 -4.4 = 0.02; ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -1.33 -1.91 -1.71 -1.05 -1.14 -4.66 -4.7 -24.11 -25.2 -4.23 3.79 -10.4 -24.23 -3.6 -3.4 -3.6 -3.4 -3.6 -3.4 -3.6 -3.4 -3.6 -3.6 -3.4 -3.6 -3.4 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ 1^{p}=113\\ 2 (P<0.\\ 20\\ 79.3\\ 68.2\\ 12.82\\ 2.503\\ 0.3\\ 0.4\\ 0.3\\ 0.3\\ 0.4\\ 0.3\\ 0.3\\ 0.4\\ 0.3\\ 0.3\\ 0.4\\ 1.4\\ 1.2\\ 2.197\\ 2.483\\ 0.3\\ 0.3\\ 0.5\\ 0.5\\ 0.3\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5$	214 145 114 10201 116, df= 20001) 43 25 25 203 35 25 203 35 25 203 38 13 813 811 811 20 0 42 42 24 22 42 20 189 41 190 189 811 40 189 190 190 190 190 190 190 190 190 190 19	$\begin{array}{c} -20.3 \\ -2.7 \\ -2.7 \\ 46 \ (P < 0 \\ \\ \\ -5 \\ -15.3 \\ -1.5 \\ -1.5 \\ -1.21 \\ -1.98 \\ -24 \\ -1.98 \\ -1.21 \\ -1.98 \\ -1.21 \\ -1.98 \\ -1.21 \\ -1.98 \\ -0.35 \\ -0.31 \\ -0.35 \\ -0.35 \\ -0.31 \\ -0.35 \\ -0.35 \\ -0.31 \\ -0.35 \\ -0.35 \\ -0.31 \\ -0.35 \\ -0.35 \\ -0.31 \\ -0.35 \\ -0.35 \\ -0.35 \\ -0.35 \\ -0.6 \\ -1.8 \\ -1.8 \\ -0.79 \\ -4.8 \\81 \\2.3 \\3.2 \\3$	3.2 3.2 3.2 0.00001 23 98.7 52.3 12.59 22.65 52.3 12.59 22.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 66622 (;) [* = 59' 41 28 200 57 806 806 806 806 806 806 806 806 806 17 7 17 17 17 17 17 17 17 137 137 137 1	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 0.2% 0.4% 0.2% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.4%	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.748, -0.38] \\ \hline \\ -0.42 \ [-0.97, 0.12] \\ -0.96 \ [-1.53, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.33] \\ -3.72 \ [-4.62, -2.83] \\ -3.72 \ [-4.62, -2.83] \\ -4.60 \ [-6.63, -3.57] \\ -3.62 \ [-4.69, -2.56] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.65, -1.24] \\ -0.49 \ [-0.74, -0.27] \\ -0.24 \ [-0.47, -0.02] \\ -0.24 \ [-0.45, -0.06] \\ -0.63 \ [-0.43, -0.42] \\ -0.50 \ [0.27, -0.47] \\ -0.24 \ [-0.48, -0.06] \\ -0.63 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.49 \ [-0.68, -0.30] \\ -0.49 \ [-0.68, -0.30] \\ -0.46 \ [-0.51, -0.20] \\ -0.46 \ [-0.61, -0.20] \\ -0.46 \ [-0.51, -0.20] \\ -0.46 \ [-0.63, -0.66] \\ -0.46 \ [-0.63, -0.66] \\ -0.46 \ [-0.63, -0.66] \\ -0.46 \ [-0.61, -0.20] \\ -0.46 \ [-0.63, -0.66] \\ -0.46 \ [-0.61, -0.20] \\ -0.46 \ [-0.51, -0.20] \\ -0.46 \ [-0$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneiky: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dickson 2001 El-Mehairy 1974 El-Mehairy 1974 El-Me	-30.92 -4.44 = 0.02; Ch : Z = 16.3; sign -23 -53.9 -60.2 -23 -23 -2.3 -2.4 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -1.14 -4.02 -2.02 -2.01 -1.14 -4.02 -2.02 -2.01 -1.14 -4.02 -2.02 -2.01 -1.05 -1.14 -4.02 -2.02 -2.03 -1.05 -1.14 -2.02 -2.03 -1.05 -1.14 -2.02 -2.03 -1.05 -1.14 -2.02 -2.03 -1.05 -1.15 -1.05 -1.15 -1.05 -1.15 -1.05 -1.15 -1.05 -1.15 -1.05 -1.15 -1.05 -1.15 -1.05 -1.15 -1.05 -1.15 -1.05 -1.15 -1.05 -1.15 -1.05 -1.15 -1.05 -1.15 -1.15 -1.15 -1.15 -1.15 -1.15 -1.15 -1.15 -1.14 -2.02 -2.02 -1.05 -1.14 -2.02 -2.02 -2.01 -1.05 -1.15 -1.14 -2.02 -2.02 -2.01 -1.15 -1.14 -2.02 -2.02 -2.01 -1.15 -1.14 -2.02 -2.02 -2.01 -1.15 -1.14 -2.02 -2.02 -2.01 -1.15 -1.14 -2.02 -2.02 -2.01 -1.15 -1.14 -2.02 -2.02 -2.02 -1.15 -1.14 -2.02 -2.02 -2.02 -1.15 -1.14 -2.02 -2.02 -2.02 -1.14 -2.02 -2.	$\begin{array}{c} 24.6\\ 3.3\\ 3.3\\ 4.4\\ y^{2}=113\\ 2 (P<0.\\ 79.3\\ 68.2\\ 2.102\\ 2.102\\ 2.102\\ 2.102\\ 2.102\\ 2.102\\ 3.12\\ 2.102\\ 3.12\\ 2.102\\ 3.12\\ 2.102\\ 3.12\\ 2.102\\ 3.12\\ 3$	214 145 114 102011 114 100001) 433 25 265 203 203 25 265 203 203 203 255 265 203 203 203 255 265 203 203 203 203 203 203 203 203 203 203	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ -2.7\\ 46 \ (P < 0\\ \\ \\ \\ -5\\ -15.3\\ -1.5\\ -3.49\\ -1.98\\ \\ \\ -1.98\\ \\ -1.21\\ \\ -1.98\\ \\ -1.21\\ \\ -1.98\\ \\ -1.21\\ \\ -1.21\\ \\ -1.21\\ \\ -1.21\\ \\ -1.21\\ \\ -1.21\\ \\ -3.1\\ \\ -0.35$	3.2 3.2 3.2 0.00001 98.7 52.3 98.7 52.3 12.59 22.65 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 6682 41 28 200 57 806 806 806 806 806 806 17 77 77 77 77 77 77 77 77 77 77 77 77	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.5% 1.3% 1.3% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.5% 1.4%	$\begin{array}{c} -0.40 \ [-0.68 \ -0.12] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.48 \ -0.38] \\ -0.42 \ [-0.97 \ -0.12] \\ -0.96 \ [-153 \ -0.39] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.48 \ -0.29] \\ -0.39 \ [-0.48 \ -0.29] \\ -0.39 \ [-0.48 \ -0.29] \\ -0.39 \ [-0.48 \ -0.29] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.25 \ [-0.52 \ -0.15] \\ -5.88 \ [-7.44 \ +4.33] \\ -3.72 \ [-4.62 \ -2.83] \\ -2.06 \ [-5.63 \ -5.63] \\ -2.96 \ [-3.93 \ -2.200] \\ -2.04 \ [-2.85 \ -3.57] \\ -3.62 \ [-4.69 \ -2.55] \\ -2.96 \ [-3.93 \ -2.200] \\ -0.24 \ [-0.47 \ -0.25] \\ -0.52 \ [-0.77 \ -0.27 \ [-0.48 \ -0.06] \\ -0.63 \ [-0.83 \ -0.42] \\ 0.50 \ (-0.21 \ -0.79] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.63 \ [-0.83 \ -0.42] \\ 0.50 \ (-0.21 \ -0.79] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.45 \ [-0.88 \ -0.06] \\ -0.45 \ [-0.88 \ -0.06] \\ -0.45 \ [-0.88 \ -0.06] \\ -0.36 \ [-0.51 \ -0.20] \\ -0.51 \ [-0.20] \\$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau? Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dickson 2001 Dougados 2007 Dickson 2001 Dougados 2007 Dickson 2001 Dickson 2001 Dickson 2001 Dickson 2001 Dickson 2003 Gibofsky 2003 Gibofsky 2003 Gibofsky 2003 Gibofsky 2003 Gibofsky 2003 Gibofsky 2003 Gibofsky 2003 Dund 1998 Paul 2009 Paul 2009 Paul 2009 Pincus 2004a Sheldon 2005 Svensson 2006h Svensson 2006h Svensson 2006h Tannenbaum 2004	-30.92 -4.4 = 0.02; Ch : Z = 16.3; sign -23 -539 -60.2 -13 -2.54 -2.01 -2.6 -1.7 -1.33 -1.91 -2.6 -1.7 -1.33 -1.91 -1.71 -1.71 -1.71 -1.71 -1.71 -1.73 -3.79 -10.4 -22.4 -2.4 -2.4 -2.4 -2.4 -2.5 -3.4 -10.5 -3.4 -10.5 -3.4 -10.5 -3.4 -10.5 -3.4 -10.5 -3.4 -10.5 -3.4 -10.5 -3.5 -3.5 -3.5 -3.5 -3.5 -3.5 -3.5 -3	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ 1^{p}=1113\\ 2(P<0.2\\ 12.82\\ 2.6\\ 12.82\\ 2.503\\ 2.186\\ 3.12\\ 2.503\\ 2.186\\ 3.12\\ 2.197\\ 2.483\\ 0.4\\ 3.03\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 1.4\\ 1.2\\ 2.503\\ 0.3\\ 0.4\\ 1.4\\ 1.2\\ 2.50\\ 0.3\\ 0.4\\ 1.4\\ 1.2\\ 2.50\\ 1.2\\ 1.2\\ 1.2\\ 1.2\\ 1.2\\ 1.2\\ 1.2\\ 1.2$	214 145 114 102011 00001) 433 25 25 203 5 26 203 5 20 203 5 20 203 5 20 203 20 20 20 20 20 20 20 20 20 20 20 20 20	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ -2.7\\ 46 \ (P < 0\\ -5\\ -16.3\\ -1.5\\ -9.49\\ -24 \\ -1.98\\ -24 \\ -1.98\\ -24 \\ -1.98\\ -1.21\\ -1.98\\ -1.21\\ -0.31\\ -0.31\\ -0.31\\ -0.31\\ -0.31\\ -0.31\\ -0.31\\ -0.31\\ -0.31\\ -0.35\\ -2.6\\ -1.8\\ -1.8\\ -1.8\\ -1.8\\ -2.6\\ -2.6\\ -2.6\\ -2.6\\ -1.8\\ -2.6\\ -2.6\\ -1.8\\ -2.6\\ -2.6\\ -3.24\\ -1.4\\ -2.4\\ -1.4\\ -1.4\\ -1.4\\ -1.4\\ \end{array}$	3.2 3.2 3.2 0.00001 23 98.7 52.3 12.59 22.65 22.65 22.65 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 75 75 75 75 75 75 80 80 80 80 80 80 80 80 80 80 80 80 80	1.2% 5.9.4% 5.9.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 0.2% 0.2% 0.2% 0.3% 1.4% 1.3% 1.3% 1.2% 1.3% 1.1% 1.3% 1.2% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.4%	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.48, -0.38] \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.63, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.25 \ [-0.33, -0.41] \\ -0.25 \ [-0.33, -0.41] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.33] \\ -3.72 \ [-4.62, -2.83] \\ -3.62 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.49 \ [-0.47, -0.02] \\ -0.25 \ [-0.47, -0.27] \\ -0.24 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.02] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.36 \ [-0.53, -0.04] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy	-30.92 -4 -4.4 = 0.02; Ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.64 -1.33 -1.91 -1.71 -1.71 -1.71 -1.75 -1.14 -4.66 -4.42 -3.379 -10.4 -2.62 -3.44 -2.66 -3.4 -2.64 -3.44 -2.65 -3.4 -2.64 -3.44 -2.65 -3.4 -2.64 -3.44 -2.65 -3.4 -2.4 -2.64 -3.2 -3.44 -3.25 -4.25 -3.25 -4.25 -5.25 -4.25 -5.25 -4.25 -5.25 -4.25 -5.25 -4.25 -5	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ \mathbf{i}^{2}=113\\ 2 (P<0.\\ 79.3\\ 68.2\\ 2.503\\ 31.2\\ 2.503\\ 2.186\\ 0.3\\ 0.4\\ 0.3\\ 0.4\\ 0.3\\ 0.5\\ 0.3\\ 0.4\\ 1.4\\ 1.8\\ 20.7\\ 2.463\\ 0.3\\ 0.5\\ 0.3\\ 0.5\\ 1.1\\ 24.7\\ 1.4\\ 4.8\\ 20.7\\ 2.65\\ 1.9\\ 78\\ 4.21\\ 2.5\\ 1.9\\ 3.3\\ 3.1\\ 3.3\\ 3.1\\ 3.3\\ 3.1\\ 3.3\\ 3.1\\ 3.3\\ 3.3$	214 145 114 1100011) 116, df= 25 25 203 35 25 203 35 25 203 3813 813 811 811 200 21 120 189 134 140 118 189 134 140 118 189 139 140 118 14 14 14 14 14 10 10 10 10 10 10 10 10 10 10 10 10 10	$\begin{array}{c} -20.3 \\ -2.7 \\ 46 \ (P < 0 \\ \\ \\ -5 \\ -15.3 \\ -1.5 \\ -9.49 \\ -1.21 \\ \\ -1.21 \\ -1.98 \\ \\ -1.21 \\ -1.98 \\ \\ -1.21 \\ -1.98 \\ \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -0.31 \\ -0.35 \\ -0$	3.2 3.2 3.2 0.00001 98.7 52.3 12.69 22.65 62.3 12.69 22.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 66622 (;) F = 59' 41 28 200 57 806 806 806 806 806 806 806 806 806 17 7 17 17 17 17 17 17 17 17 17 137 89 96 137 137 82 382 382 382 382 382 382 382 382 382	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.4% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4%	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.74, -0.38] \\ \hline \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-153, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.32, -0.13] \\ -0.28 \ [-0.32, -0.13] \\ -0.39 \ [-0.48, -0.28] \\ -0.25 \ [-0.32, -0.13] \\ -0.39 \ [-0.48, -0.28] \\ -0.25 \ [-0.35, -0.16] \\ -5.88 \ [-7.44, -4.33] \\ -3.72 \ [-462, -2.83] \\ -4.60 \ [-5.63, -3.57] \\ -3.62 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -0.24 \ [-0.47, -0.02] \\ -0.52 \ [-0.77, -0.27] \\ -0.24 \ [-0.47, -0.02] \\ -0.52 \ [-0.77, -0.27] \\ -0.24 \ [-0.48, -0.28] \\ -0.52 \ [-0.77, -0.27] \\ -0.24 \ [-0.48, -0.06] \\ -0.63 \ [-0.63, -0.42] \\ 0.50 \ [-0.27, \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.59, -0.76] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.52, -0.71] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.58, -0.06] \\ -0.32 \ [-0.58, -0.06] \\ -0.32 \ [-0.58, -0.06] \\ -0.32 \ [-0.58, -0.06] \\ -0.32 \ [-0.58, -0.06] \\ -0.32 \ [-0.58, -0.06] \\ -0.32 \ [-0.58, -0.06] \\ -0.32 \ [-0.58, -0.06] \\ -0.32 \ [-0.58, -0.06] \\ -0.35 \ [-0.58, -0.06] \\ -0.$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau"? Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLernos 2011 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974 El-	-30.92 -4.4 -4.4 = 0.02; Ch : Z = 16.3; sign -23 -53.8 -60.2 -13 -23 -53.8 -60.2 -202 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -1.7 -1.14 -4.23 -1.71 -1.14 -4.63 -3.79 -0.44 -2.64 -3.1 -2.64 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.45 -3.55 -3.45 -3.55 -3.	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ p^{2}=1113\\ 2(P<0.2\\ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, $	214 4 145 114 140201 114 10201 433 25 25 25 25 26 20 33 81 32 35 55 26 81 33 81 33 81 33 81 31 81 11 12 20 12 11 1900 42 22 12 11 1900 42 22 12 11 1900 42 22 11 1900 42 20 11 134 148 108 81 81 118 108 81 81 189 94 1393 32 800 391 393 32 800 31 23 34 91 148 118 99 14 487 148 118 99 14 487 148 118 99 14 487 148 118 99 14 487 148 118 99 14 487 148 148 148 148 148 148 148 148 148 148	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ -2.7\\ 46 \ (P < 0\\ \\ \\ \end{array}$	3.2 3.2 3.2 0.00001 98.7 52.3 98.7 52.3 12.59 22.65 1.992 24.75 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 6682 1, F = 59' 41 28 200 57 806 806 806 17 17 17 17 17 17 17 17 137 137 137 137	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4% 1.3% 1.3% 1.2% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4	$\begin{array}{c} -0.40 \ [-0.68 \ -0.12] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.42 \ [-0.97 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.42 \ [-0.97 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.42 \ [-0.97 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.28 \ [-0.47 \ -0.08] \\ -0.38 \ [-0.48 \ -0.29] \\ -0.38 \ [-0.48 \ -0.29] \\ -0.38 \ [-0.48 \ -0.29] \\ -0.38 \ [-0.48 \ -0.29] \\ -0.38 \ [-0.48 \ -0.29] \\ -0.38 \ [-0.48 \ -0.29] \\ -0.25 \ [-0.55 \ -0.55] \\ -5.88 \ [-7 \ 44 \ -4.33] \\ -3.72 \ [-4.62 \ -2.55] \\ -2.96 \ [-3.93 \ -2.200] \\ -2.04 \ [-2.65 \ -1.24] \\ -0.49 \ [-0.77 \ -0.27] \\ -0.24 \ [-0.47 \ -0.05] \\ -0.52 \ [-0.77 \ -0.27] \\ -0.24 \ [-0.48 \ -0.05] \\ -0.63 \ [-0.83 \ -0.42] \\ -0.50 \ [-0.77 \ -0.27] \\ -0.27 \ [-0.48 \ -0.05] \\ -0.63 \ [-0.83 \ -0.42] \\ -0.50 \ [-0.32] \ -0.46 \ -0.18] \\ -0.32 \ [-0.46 \ -0.18] \\ -0.32 \ [-0.46 \ -0.18] \\ -0.32 \ [-0.46 \ -0.18] \\ -0.32 \ [-0.46 \ -0.18] \\ -0.32 \ [-0.47 \ -0.26] \\ -0.36 \ [-0.53 \ -0.20] \\ -0.32 \ [-0.47 \ -0.21] \\ -0.36 \ [-0.53 \ -0.21] \\ -0.36 \ [-0.54 \ -0.21] \\ -0.36 \ [-0.54 \ -0.21] \\ -0.36 \ [-0.54 \ -0.21] \\ -0.36 \ [-0.54 \ -0.21] \\ -0.36 \ [-0.54 \ -0.21] \\ -0.36 \ [-0.54 \ -0.21] \\ -0.38 \ [-0.34 \ -0.21] \\ -0.38 \ [-0.34 \ -0.21] \\ -0.38 \ [-0.34 \ -0.21] \\ -0.38 \ [-0.34 \ -0.21] \\ -0.38 \ [-0.34 \ -0.21] \\ -0.38 \ [-0.34 \ -0.21] \\ -0.38 \ [-0.34 \ -0.34 \ -0.21] \\ -0.38 \ [-0.34 \ -0.34 \ -0.31] \\ -0.38 \ [-0.34 \ -0.34 \ -0.31] \\ -0.38 \ [-0.34 \ -0.34 \ -0.31] \\ -0.38 \ [-0.34 \ -0.34 \ -0.31] \\ -0.38 \ [-0.34 \ -0.34 \ -0.34 \ -0.31] \\ -0.38 \ [-0.34 \ -0.3$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau? Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974 El-Meh	-30.92 -4.4 = 0.02; ch : Z = 16.3; sign -23 -53.9 -60.2 -13 -2.54 -2.02 -2.01 -2.6 -2.01 -2.6 -1.13 -1.91 -1.71 -1.91 -1.71 -1.05 -1.14 -4.6 -4.7 -24.1 -25.2 -4.23 3.79 -10.4 -25.2 -3.4 -3.4 -3.6 -3.4 -3.6 -3.6 -3.6 -3.2 -2.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.6 -3.6 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6	24.6 3.3 4.4 200 200 79.3 68.2 2.503 2.186 2.197 2.483 0.3 0.4 0.3 0.4 0.3 0.4 0.3 0.4 1.247 1.41 24.7 1.41 24.7 1.41 24.7 1.41 24.7 1.41 24.7 1.41 24.7 1.43 0.3 0.3 0.3 0.44 1.41 24.7 1.41 24.7 1.41 24.7 1.41 24.7 1.43 0.3 0.3 0.3 0.44 1.41 24.7 1.44 2.197 1.44 1.41 2.457 1.44 1.41 2.457 1.44 1.4	214 145 114 10201 116, df= 200 203 262 203 262 203 203 262 203 203 813 813 811 811 200 201 222 21 201 201 201 189 422 21 190 189 41 190 189 41 401 401 401 401 401 401 401 401 401	$\begin{array}{c} -20.3 \\ -2.7 \\ -2.7 \\ 46 \ (P < 0 \\ \\ \\ -56 \\ -16.3 \\ -1.6 \\ -1.6 \\ -1.6 \\ -1.98 \\ -24 \\ -1.98 \\ -1.21 \\ -1.98 \\ -1.98 \\ -1.21 \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -1.98 \\ -2.6 \\ -2.1 \\ -2.4 \\ -1.4 \\ -2.4 \\ -2.4 \\ -2.4 \\ -2.4 \\ -2.4 \\ -2.4 \\ -2.4 \\ -2.4 \\ -2.4 \\ -2.4 \\ -2.4 \\ -2.4 \\ -2.7 \\ -2.7 \\ -2.7 \\ -2.7 \\ -2.7 \\ -2.7 \\ -2.7 \\ -2.4 \\ $	3.2 3.2 3.2 0.00001 23 98.7 52.3 12.50 22.65 2.2475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 75 75 75 75 75 75 80 80 80 80 80 80 80 80 80 80 80 80 80	1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.4% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.74, -0.38] \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.53, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.29] \\ -0.38 \ [-0.48, -0.28] \\ -0.25 \ [-0.35, -0.15] \\ -5.68 \ [-7, 44, -4.33] \\ -3.72 \ [-4.62, -2.83] \\ -4.60 \ [-5.63, -3.57] \\ -3.62 \ [-4.69, -2.56] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.45 \ [-0.74, -0.27] \\ -0.24 \ [-0.47, -0.06] \\ -0.63 \ [-0.47, -0.06] \\ -0.63 \ [-0.63, -0.06] \\ -0.65 \ [-0.63, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.36 \ [-0.53, -0.06] \\ -0.36 \ [-0.52, -0.11] \\ -0.36 \ [-0.52, -0.21] \\ -0.36 \ [-0.52, -0.21] \\ -0.36 \ [-0.52, -0.21] \\ -0.36 \ [-0.52, -0.21] \\ -0.34 \ [-0.34, -0.03] \\ -0.34 \ [-0.34, -0.03] \\ -0.49 \ [-0.35, -0.04] \\ -0.34 \ [-0.34, -0.03] \\ -0.49 \ [-0.35, -0.04] \\ -0.34 \ [-0.34, -0.03] \\ -0.49 \ [-0.35, -0.04] \\ -0.36 \ [-0.52, -0.21] \\ -0.34 \ [-0.34, -0.03] \\ -0.49 \ [-0.35, -0.04] \\ -0.34 \ [-0.34, -0.03] \\ -0.49 \ [-0.35, -0.04] \\ -0.36 \ [-0.52, -0.04] \\ -0.34 \ [-0.34, -0.03] \\ -0.49 \ [-0.35, -0.04] \\ -0.50 \ [-0.54, -0.03] \\ -0.48 \ [-0.5$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneiky: Tau? Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Diel-Mehairy 1974 El-Mehairy 197	-30.92 -4.4 = 0.02; Ch : Z = 16.3; sign -23 -53.9 -60.2 -23 -23 -2.3 -2.3 -2.3 -2.4 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -1.14 -4.202 -2.01 -1.14 -4.202 -2.41 -2.42 -3.3 -3.4 -16.24 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2	24.6 3.3 4.4 µ²=1113 2 (P < 0.7 79.3 68.2 2.107 2.503 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.5 0.5 4.1 1.2 4.7 2.186 0.3 0.3 0.3 0.3 0.3 0.3 0.4 2.197 2.483 0.3 0.3 0.3 0.4 2.197 2.483 0.3 0.3 0.3 0.4 2.197 2.483 0.3 0.3 0.3 0.4 2.197 2.483 0.3 0.3 0.3 0.4 2.197 2.483 0.3 0.3 0.3 0.4 0.5 1.2 2.186 0.5 1.2 2.186 0.5 1.2 2.186 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.5 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4	214 145 114 100001) 433 255 265 203 355 813 813 813 813 811 811 800 42 21 203 203 813 813 813 813 813 813 813 814 811 190 0 0 201 190 202 21 190 0 201 189 189 189 189 189 189 189 189 189 18	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ -2.7\\ \end{array}$	3.2 3.2 3.2 0.00001 98.7 12.69 22.65 62.3 12.69 22.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 6682 20 41 28 200 57 806 806 806 806 806 806 806 806 17 7 17 17 17 17 17 17 17 17 17 17 17 1	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4	$\begin{array}{c} -0.40 \ [-0.68 - 0.12] \\ -0.43 \ [-0.72 , -0.13] \\ -0.43 \ [-0.72 , -0.13] \\ -0.43 \ [-0.72 , -0.13] \\ -0.42 \ [-0.97 , -0.12] \\ -0.96 \ [-153 , -0.39] \\ -0.28 \ [-0.47 , -0.08] \\ -0.28 \ [-0.47 , -0.08] \\ -0.28 \ [-0.32 , -0.13] \\ -0.39 \ [-0.48 , -0.28] \\ -0.39 \ [-0.48 , -0.28] \\ -0.39 \ [-0.48 , -0.28] \\ -0.39 \ [-0.48 , -0.28] \\ -0.38 \ [-0.48 , -0.28] \\ -0.38 \ [-0.48 , -0.28] \\ -0.38 \ [-0.48 , -0.28] \\ -0.38 \ [-0.48 , -0.28] \\ -0.38 \ [-0.48 , -0.28] \\ -0.48 \ [-0.48 , -0.28] \\ -0.48 \ [-0.48 , -0.28] \\ -0.52 \ [-0.77 , -0.27] \\ -0.24 \ [-0.47 , -0.27] \\ -0.24 \ [-0.47 , -0.27] \\ -0.24 \ [-0.47 , -0.27] \\ -0.24 \ [-0.48 , -0.08] \\ -0.63 \ [-0.83 , -0.20] \\ -0.63 \ [-0.83 , -0.42] \\ -0.50 \ [-0.27 \ [-0.48 , -0.08] \\ -0.32 \ [-0.48 , -0.08] \\ -0.32 \ [-0.48 , -0.08] \\ -0.32 \ [-0.48 , -0.08] \\ -0.32 \ [-0.48 , -0.08] \\ -0.32 \ [-0.47 , -0.18] \\ -0.32 \ [-0.47 , -0.71] \\ -0.32 \ [-0.47 , -0.16] \\ -0.36 \ [-0.35 \ [-0.04] \\ -0.37 \ [-0.75 , -0.01] \\ -0.$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau? Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dickson 2001 Dougados 2007 Dickson 2007 Dickson 2007 Dickson 2007 El-Mehairy 1974 El-Mehairy 1974 El-M	-30.92 -4.4 -4.4 = 0.02; Ch : Z = 16.3; sign -23 -538 -60.2 -13 -2.54 -2.54 -2.54 -2.54 -2.54 -2.54 -2.54 -2.54 -2.54 -1.77 -1.33 -1.91 -1.14 -4.6 -4.7 -24.1 -25.2 -4.23 3.79 -10.4 -21.8 -3.4 -12.8 -3.4 -12.8 -3.4 -12.6 -1.77 -1.4 -2.6 -1.77 -1.4 -2.6 -1.77 -1.4 -2.6 -3.4 -3.4 -2.6 -3.4 -3.4 -2.6 -3.4 -3.4 -2.6 -3.4 -3.4 -3.4 -3.4 -3.4 -3.4 -3.4 -3.4	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ 20\\ 0\\ 20\\ 78.3\\ 2\\ (P < 0.2\\ 12.82\\ 2.503\\ 2.186\\ 2.197\\ 2.483\\ 0.3\\ 2.197\\ 2.483\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.3\\ 0.$	214 4 145 114 140201 114 102001) 433 25 25 203 35 525 25 813 3813 811 811 811 811 100 42 242 21 200 42 21 190 189 134 42 140 188 181 189 94 391 393 3280 491 481 487 56 56	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ -2.7\\ 46 \ (P < 0\\ -5\\ -16.3\\ -1.5\\ -9.49\\ -24\\ -1.21\\ -1.98\\ -24\\ -1.21\\ -1.98\\ -1.21\\ -1.98\\ -1.21\\ -1.98\\ -2.4\\ -3.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -2.6\\ -18\\ -1.8\\ -2.8\\ -2.6\\ -2.8\\ -2$	3.2 3.2 3.2 0.00001 23 98.7 52.3 12.59 22.65 22.65 22.65 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 75 75 75 75 75 75 75 80 80 80 80 80 80 80 80 80 80 80 80 80	1.2% 5.9.4% 5.9.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.1% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.4% 1.1%	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.63, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.48, -0.29] \\ -0.25 \ [-0.33, -0.14] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.3] \\ -3.72 \ [-4.62, -2.83] \\ -3.62 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.48 \ [-0.24] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.33] \\ -3.72 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.49 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.06] \\ -0.25 \ [-0.47, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.63 \ [-0.63, -0.42] \\ -0.50 \ [-0.21, -0.74] \\ -0.51 \ [-0.63, -0.06] \\ -0.32 \ [-0.46, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.36 \ [-0.52, -0.21] \\ -0.37 \ [-0.54, -0.03] \\ -0.37 \ [-0.56, -0.04] \\ -0.37 \ [-0.56, -0.04] \\ -0.37 \ [-0.56, -0.04] \\ -0.57 \ [-0.56, -0.04]$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity. Tau?: Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974 El-Meha	-30.92 -4.4 = 0.02; Ch : Z = 16.3; sign -23 -53.9 -60.2 -23 -23 -2.3 -2.3 -2.3 -2.4 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -1.14 -4.202 -2.01 -1.14 -4.202 -2.41 -2.42 -3.3 -3.4 -16.24 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2	24.6 3.3 4.4 µ²=1113 2 (P < 0.7 79.3 68.2 2.107 2.182 2.182 2.197 2.483 0.3 0.3 0.3 0.4 0.5 0.5 4.1 1.24.7 2.65 4.1 2.47 2.65 4.1 2.47 2.65 4.1 2.47 2.65 4.1 2.47 2.65 4.1 2.47 2.65 4.1 2.47 2.65 4.1 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3	214 145 114 116, df= 25 203 25 203 25 203 25 203 25 203 325 203 3813 813 811 811 200 21 12 20 21 21 20 189 140 148 148 148 148 148 148 148 148 149 149 149 149 149 149 149 149 149 149	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ -2.7\\ \end{array}$	3.2 3.2 3.2 0.00001 98.7 12.69 22.65 62.3 12.69 22.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 75 75 75 75 75 75 75 80 80 80 80 80 80 80 80 80 80 80 80 80	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.4% 1.3% 1.4% 1.1%	$\begin{array}{c} -0.40 \ [-0.68 \ -0.12] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.74 \ -0.38] \\ \hline \\ -0.42 \ [-0.97 \ -0.12] \\ -0.64 \ [-0.37 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.22 \ [-0.47 \ -0.08] \\ -0.22 \ [-0.32 \ -0.13] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.22 \ [-0.32 \ -0.15] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-7.44 \ -4.33] \\ -3.72 \ [-4.62 \ -2.83] \\ -4.60 \ [-5.63 \ -3.57] \\ -3.62 \ [-4.69 \ -2.55] \\ -2.96 \ [-3.93 \ -2.00] \\ -0.44 \ [-0.74 \ -0.25] \\ -0.52 \ [-0.77 \ -0.27] \\ -0.24 \ [-0.47 \ -0.02] \\ -0.52 \ [-0.77 \ -0.27] \\ -0.24 \ [-0.47 \ -0.07] \\ -0.24 \ [-0.47 \ -0.07] \\ -0.27 \ [-0.48 \ -0.06] \\ -0.63 \ [-0.63 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.47 \ -0.16] \\ -0.36 \ [-0.52 \ -0.07] \\ -0.18 \ [-0.35 \ -0.04] \\ -0.37 \ [-0.75 \ -0.01] \\ -0.37 \ [-0.75 \ -$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau"? Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 El-Mehairy 1974 El-Mehairy 1974 El	-30.92 -4.44 = 0.02; Ch : Z = 16.3; sign -23 -53.9 -60.2 -13 -23 -53.9 -60.2 -202 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -2.01 -2.02 -1.17 -2.04 -2.02 -1.17 -1.14 -4.66 -3.1 -2.41 -2.62 -3.16.33 -2.54 -3.1 -2.64 -3.1 -2.64 -3.1 -2.64 -3.1 -2.64 -3.1 -2.64 -3.1 -2.64 -3.1 -2.64 -3.1 -2.64 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ 1^{2}=1113\\ 2(P<0.79,3\\ 68.2\\ 2.102\\ 2.12,82\\ 2.12,82\\ 2.12,82\\ 2.137\\ 2.483\\ 0.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 1.4\\ 1.8\\ 20.7\\ 1.28,5\\ 4.1\\ 1.28,1\\ 2.186\\ 0.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 0.5\\ 0.3\\ 0.4\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5$	214 4 145 114 140201 114 10201 433 25 25 25 26 203 203 25 26 203 203 26 20 20 20 20 20 20 20 20 20 20 20 20 20	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ -2.7\\ 46 \ (P < 0\\ \\ \\ \end{array}$	3.2 3.2 3.2 0.00001 23 98.7 52.3 98.7 52.3 52.3 1.992 22.65 21.992 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 6682 41 28 200 57 806 806 806 806 806 806 17 17 17 17 17 17 17 17 17 13 7 13 7 1	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 0.2% 0.4% 0.3% 0.3% 0.4% 0.4% 0.5% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4% 1.3% 1.3% 1.3% 1.3% 1.2% 1.4% 1.3% 1.4	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.63, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.48, -0.29] \\ -0.25 \ [-0.33, -0.14] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.3] \\ -3.72 \ [-4.62, -2.83] \\ -3.62 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.48 \ [-0.24] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.33] \\ -3.72 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.49 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.06] \\ -0.25 \ [-0.47, -0.06] \\ -0.32 \ [-0.48, -0.06] \\ -0.63 \ [-0.63, -0.42] \\ -0.50 \ [-0.21, -0.74] \\ -0.51 \ [-0.63, -0.06] \\ -0.32 \ [-0.46, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.32 \ [-0.47, -0.06] \\ -0.36 \ [-0.52, -0.21] \\ -0.37 \ [-0.54, -0.03] \\ -0.37 \ [-0.56, -0.04] \\ -0.37 \ [-0.56, -0.04] \\ -0.37 \ [-0.56, -0.04] \\ -0.57 \ [-0.56, -0.04]$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogenetik: Tau* 2 Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Diel-Mehairy 1974 El-Mehairy 2003 Gibofsky 2003 Gibofsky 2003 Gibofsky 2003 Elund 1998 Paul 2009 Pincus 2004a Pincus 2004b Schnitzer 2004 Sheldon 2005 Svensson 2006h Svensson 2006h Svensson 2006h Tannenbaum 2004 Tannenbaum 2004 Tannenbaum 2004 Truitt 2001 Truitt 2001 Truitt 2001	-30.92 -4.4 -4.4 = 0.02; Ch : Z = 16.3; sign -23 -53.9 -60.2 -13 -2.54 -2.02 -2.01 -2.6 -2.01 -2.6 -2.11 -2.6 -1.13 -1.71 -1.05 -1.14 -4.6 -4.7 -24.1 -25.2 -4.23 3.79 -10.4 -24.4 -3.4 -3.4 -16.62 -3.4 -3.2 -2.4 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -2.6 -3.2 -2.6 -3.2 -3.6 -3.2 -2.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -2.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6	24.6 3.3 4.4 ¹ ² = 1113 2 (P < 0. 200 79.3 68.2 2.102 2.102 2.103 0.3 0.3 0.3 0.3 0.4 1.2.82 2.107 2.483 0.3 0.3 0.3 0.3 0.4 4.1 24.7 1.2.47 1.4.1 24.7 1.4.1 24.7 1.4.1 24.7 1.4.1 24.7 1.5.03 0.3 0.3 0.4 4.4 1.2.2 2.197 0.3 0.3 0.3 0.4 4.4 1.2.2 2.197 1.2.82 2.197 2.483 0.3 0.3 0.3 0.4 4.4 1.2.2 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 1.2.82 1.2.82 2.197 1.2.82 1.2.97 1.2.82 1.2.97 1.4.1 2.4.7 1.4 8.20.7 1.9.78 3.4 3.3 3.3 2.9.77 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 3.8 4.2 3.8 4.3 3.3 3.3 2.9.77 2.9.77 2.4.21 3.8 4.3 2.9.77 2.9.77 2.4.21 3.8 4.3 3.3 3.3 2.9.77 3.9.77 3.9	214 145 114 10201 116, df= 200001) 433 252 203 203 203 203 203 203 813 813 811 811 200 202 21 202 21 202 21 190 189 42 21 200 202 21 190 189 42 21 190 189 44 301 189 44 301 189 44 301 189 44 301 189 44 301 189 44 301 189 44 301 189 44 302 205 205 205 205 205 205 205 205 205 2	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ -2.7\\ 46 \ (P < 0\\ \\ \\ \end{array}$	3.2 3.2 3.2 0.00001 23 98.7 52.3 98.7 52.3 52.3 1.992 22.65 21.992 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 6682 41 28 200 57 806 806 806 806 806 806 17 17 17 17 17 17 17 17 17 13 7 13 7 1	1.2% 1.2% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 0.2% 0.4% 0.3% 0.3% 0.4% 0.4% 0.5% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.4% 1.3% 1.3% 1.3% 1.3% 1.2% 1.4% 1.3% 1.4	$\begin{array}{c} -0.40 \ [-0.68 \ -0.12] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.74 \ -0.38] \\ \hline \\ -0.42 \ [-0.97 \ -0.12] \\ -0.64 \ [-0.37 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.22 \ [-0.47 \ -0.08] \\ -0.22 \ [-0.32 \ -0.13] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.22 \ [-0.32 \ -0.15] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-7.44 \ -4.33] \\ -3.72 \ [-4.62 \ -2.83] \\ -4.60 \ [-5.63 \ -3.57] \\ -3.62 \ [-4.69 \ -2.55] \\ -2.96 \ [-3.93 \ -2.00] \\ -0.44 \ [-0.74 \ -0.25] \\ -0.52 \ [-0.77 \ -0.27] \\ -0.24 \ [-0.47 \ -0.02] \\ -0.52 \ [-0.77 \ -0.27] \\ -0.24 \ [-0.47 \ -0.07] \\ -0.24 \ [-0.47 \ -0.07] \\ -0.27 \ [-0.48 \ -0.06] \\ -0.63 \ [-0.63 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.47 \ -0.16] \\ -0.36 \ [-0.52 \ -0.07] \\ -0.18 \ [-0.35 \ -0.04] \\ -0.37 \ [-0.75 \ -0.01] \\ -0.37 \ [-0.75 \ -$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Diekson 2001 Dougados 2007 Diekson 2001 Dougados 2007 Diekson 2001 Dougados 2007 Diekson 2001 Diekson 2003 El-Mehairy 1974 El-Mehairy 1974 El-Meh	-30.92 -4.4 -4.4 = 0.02; Ch : Z = 16.3; sign -23 -53.9 -60.2 -13 -2.54 -2.02 -2.01 -2.6 -2.01 -2.6 -2.11 -2.6 -1.13 -1.71 -1.05 -1.14 -4.6 -4.7 -24.1 -25.2 -4.23 3.79 -10.4 -24.4 -3.4 -3.4 -16.62 -3.4 -3.2 -2.4 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -2.6 -3.2 -2.6 -3.2 -3.6 -3.2 -2.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -2.6 -3.2 -2.6 -3.2 -3.6 -3.2 -2.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.2 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6 -3.6	24.6 3.3 4.4 ¹ ² = 1113 2 (P < 0. 200 79.3 68.2 2.102 2.102 2.103 0.3 0.3 0.3 0.3 0.4 1.2.82 2.107 2.483 0.3 0.3 0.3 0.3 0.4 4.1 24.7 1.2.47 1.4.1 24.7 1.4.1 24.7 1.4.1 24.7 1.4.1 24.7 1.5.03 0.3 0.3 0.4 4.4 1.2.2 2.197 0.3 0.3 0.3 0.4 4.4 1.2.2 2.197 1.2.82 2.197 2.483 0.3 0.3 0.3 0.4 4.4 1.2.2 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 1.2.82 1.2.82 2.197 1.2.82 1.2.97 1.2.82 1.2.97 1.4.1 2.4.7 1.4 8.20.7 1.9.78 3.4 3.3 3.3 2.9.77 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 2.4.21 3.8 4.2 3.8 4.3 3.3 3.3 2.9.77 2.9.77 2.4.21 3.8 4.3 2.9.77 2.9.77 2.4.21 3.8 4.3 3.3 3.3 2.9.77 3.9.77 3.9	214 4 145 114 114 102011 114 100001) 433 25 25 203 5 25 203 5 203 5 203 5 203 5 203 5 203 8 13 811 811 811 811 811 811 811 811 8	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ -2.7\\ 46 \ (P < 0\\ \\ \\ \end{array}$	3.2 3.2 3.2 0.00001 23 98.7 52.3 12.50 22.65 22.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 75 75 75 75 75 75 75 80 80 80 80 80 80 80 80 80 80 80 80 80	1.2% 59.4% 59.4% 0.9% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 0.2% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.63, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.3] \\ -3.72 \ [-4.62, -2.83] \\ -3.72 \ [-4.62, -2.83] \\ -3.62 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.49 \ [-0.48, -0.22] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.3] \\ -3.72 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.49 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.06] \\ -0.63 \ [-0.63, -0.42] \\ -0.63 \ [-0.63, -0.42] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.37 \ [-0.56, -0.01] \\ -0.56 \ [-0.71, -0.42] \\ \end{array}$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau* Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dickson 2007 Dougados 2007 Dickson 2007 Dickson 2007 Dickson 2007 Dickson 2007 Dickson 2007 Dickson 2007 El-Mehairy 1974 El-Mehairy 1974	-30.92 -4. -4.4 = 0.02; ch : Z = 16.32 sign -23 -53.9 -60.2 -13 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -2.02 -2.01 -2.64 -1.33 -1.91 -1.71 -1.05 -1.14 -4.66 -4.7 -2.4.13 -2.62 -3.4 -2.4 -2.63 -1.14 -2.62 -3.4 -3.6 -3.4 -3.4 -3.6 -3.4 -3.4 -3.6 -3.1 -3.2 -2.4 -3.6 -3.1 -3.2 -2.4 -3.5 -3.4 -3.4 -3.6 -3.1 -3.2 -2.4 -3.5 -3.4 -3.4 -3.6 -3.1 -3.2 -2.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.4 -3.5 -3.5 -3.5 -3.5 -3.5 -3.5 -3.5 -3.5	24.6 3.3 4.4 200 200 79.3 68.2 12.82 2.503 0.3 0.3 0.4 0.3 0.3 0.4 0.3 0.4 0.3 0.4 1.24.7 1.4.1 24.7 1.4.4 26.5 0.3 0.3 0.4 0.3 0.4 1.24.7 1.2.82 2.197 2.483 0.3 0.4 0.3 0.4 1.2.82 2.197 2.483 0.3 0.3 0.4 1.2.82 2.197 2.483 0.3 0.4 0.3 0.4 1.2.82 2.197 2.483 0.3 0.4 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.82 2.197 1.2.83 0.3 0.3 0.4 1.2.82 1.2.82 1.1.82 1.1.82 1.1.82 1.1.83 1.1.83 1.1.83 1.1.84 1.2.84 1.2.85 1.2.82 1.1.83 1.1.84 1.1.24 1.2.85 1.2.85 1.2.82 1.1.83 1.1.83 1.1.84 1.2.84 1.2.85	214 145 114 10201 116, df= 200001) 433 255 203 252 203 203 252 203 813 813 811 811 200 42 42 22 42 20 201 190 189 811 190 189 193 280 123 193 280 123 280 123 280 280 123 280 280 283 280 283 283 280 293 280 293 280 293 280 293 280 293 280 293 280 293 280 293 293 293 293 293 293 293 293 293 293	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ 46 \ (P < 0\\ -5\\ -15.3\\ -1.5\\ -9.49\\ -24\\ -1.98\\ -24\\ -1.98\\ -1.21\\ -1.98\\ -1.21\\ -1.98\\ -1.21\\ -1.98\\ -1.21\\ -1.98\\ -1.8\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.6\\ -2.6\\ -2.6\\ -2.6\\ -2.6\\ -81\\ -2.3\\ -6.75\\ -3.24\\ -1.4\\ -2.4\\ -2.4\\ -1.4\\ -2.4\\ -2.4\\ -5.02\\ -5.02\\ 36 \ (P < 0\\ -2.6\\ -2.$	3.2 3.2 3.2 0.00001 98.7 52.3 12.59 22.65 62.3 12.59 22.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 75 75 75 75 75 75 75 80 80 80 80 80 80 80 80 80 80 80 80 80	1.2% 59.4% 59.4% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 0.2% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4	$\begin{array}{c} -0.40 \ [-0.68 \ -0.12] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.72 \ -0.13] \\ -0.43 \ [-0.74 \ -0.38] \\ \hline \\ -0.42 \ [-0.97 \ -0.12] \\ -0.64 \ [-0.37 \ -0.12] \\ -0.96 \ [-1.53 \ -0.39] \\ -0.22 \ [-0.47 \ -0.08] \\ -0.22 \ [-0.32 \ -0.13] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.22 \ [-0.32 \ -0.15] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-0.48 \ -0.28] \\ -0.38 \ [-7.44 \ -4.33] \\ -3.72 \ [-4.62 \ -2.83] \\ -4.60 \ [-5.63 \ -3.57] \\ -3.62 \ [-4.69 \ -2.55] \\ -2.96 \ [-3.93 \ -2.00] \\ -0.44 \ [-0.74 \ -0.25] \\ -0.52 \ [-0.77 \ -0.27] \\ -0.24 \ [-0.47 \ -0.02] \\ -0.52 \ [-0.77 \ -0.27] \\ -0.24 \ [-0.47 \ -0.07] \\ -0.24 \ [-0.47 \ -0.07] \\ -0.27 \ [-0.48 \ -0.06] \\ -0.63 \ [-0.63 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.48 \ -0.06] \\ -0.32 \ [-0.47 \ -0.16] \\ -0.36 \ [-0.52 \ -0.07] \\ -0.18 \ [-0.35 \ -0.04] \\ -0.37 \ [-0.75 \ -0.01] \\ -0.37 \ [-0.75 \ -$	
Wiesenhutter 2005 Wittenberg 2006 Subtotal (95% CI) Heterogeneity: Tau ² : Test for overall effect 55.2.2 Non-Flare Des Biegert 2004 Case 2003 DeLemos 2011 Dickson 2001 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Dougados 2007 Diel-Menairy 1974 El-Mehairy 1974	-30.92 -4.4 -4.4 = 0.02; Ch : Z = 16.3; sign -23 -53.9 -60.2 -13 -23 -53.9 -60.2 -202 -2.01 -2.6 -1.7 -2.6 -1.7 -1.14 -2.02 -2.01 -1.14 -2.02 -2.01 -1.7 -1.14 -4.23 3.79 -1.14 -2.4 -2.3 -3.6 -3.4 -3.4 -3.4 -3.4 -3.4 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2 -3.2	$\begin{array}{c} 24.6\\ 3.3\\ 4.4\\ \mu^{2}=1113\\ 2(P<0.79,3\\ 68.2\\ 2.102\\ 12.82\\ 2.103\\ 0.4\\ 3.12\\ 2.103\\ 0.4\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5\\ 0.5$	214 4 145 114 102011 114 102011 114 102011 433 25 25 25 21 20 35 20 35 25 21 20 35 20 35 25 21 20 35 20 35 21 20 21 20 21 20 21 20 21 20 20 21 20 20 21 20 20 20 20 20 20 20 20 20 20 20 20 20	$\begin{array}{c} -20.3\\ -2.7\\ -2.7\\ 46 \ (P < 0\\ -5\\ -15.3\\ -1.5\\ -9.49\\ -24\\ -1.98\\ -24\\ -1.98\\ -1.21\\ -1.98\\ -1.21\\ -1.98\\ -1.21\\ -1.98\\ -1.21\\ -1.98\\ -1.8\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.35\\ -0.6\\ -2.6\\ -2.6\\ -2.6\\ -2.6\\ -81\\ -2.3\\ -6.75\\ -3.24\\ -1.4\\ -2.4\\ -2.4\\ -1.4\\ -2.4\\ -2.4\\ -5.02\\ -5.02\\ 36 \ (P < 0\\ -2.6\\ -2.$	3.2 3.2 3.2 0.00001 98.7 52.3 12.59 22.65 62.3 12.59 22.475 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	755 75 75 75 75 75 75 75 75 75 80 80 80 80 80 80 80 80 80 80 80 80 80	1.2% 59.4% 59.4% 0.8% 0.8% 0.8% 1.3% 1.4% 1.4% 1.4% 1.4% 0.2% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4	$\begin{array}{c} -0.40 \ [-0.68, -0.12] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.43 \ [-0.72, -0.13] \\ -0.42 \ [-0.97, -0.12] \\ -0.96 \ [-1.63, -0.39] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.28 \ [-0.47, -0.08] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.3] \\ -3.72 \ [-4.62, -2.83] \\ -3.72 \ [-4.62, -2.83] \\ -3.62 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.49 \ [-0.48, -0.22] \\ -0.25 \ [-0.35, -0.15] \\ -5.88 \ [-7.44, -4.3] \\ -3.72 \ [-4.69, -2.55] \\ -2.96 \ [-3.93, -2.00] \\ -2.04 \ [-2.85, -1.24] \\ -0.49 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.02] \\ -0.24 \ [-0.47, -0.06] \\ -0.63 \ [-0.63, -0.42] \\ -0.63 \ [-0.63, -0.42] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.36 \ [-0.54, -0.61] \\ -0.37 \ [-0.56, -0.01] \\ -0.56 \ [-0.71, -0.42] \\ \end{array}$	

Figure 2: Forest plot of absolute pain score for NSAID versus Placebo for flare versus non-flare trial design.

	1	ISAID		Р	lacebo		9	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
54.2.1 Flare Design									
Bingham 2007a	42.8	22.9	236	54.2	24.6	126	3.2%	-0.48 [-0.70, -0.26]	
Bingham 2007a	39.6	22.9	228	54.2	24.6	126	3.2%	-0.62 [-0.84, -0.40]	
Bingham 2007b	40.6	24.1	246	51.8	24.8	111	3.2%	-0.46 [-0.69, -0.23]	
Bingham 2007b	41.6	23.7	243	51.8	24.8	111	3.2%	-0.42 [-0.65, -0.20]	
Bocanegra 1999	-2.63	2.83	154	-1.16	2.55	91	3.0%	-0.54 [-0.80, -0.27]	
Bocanegra 1999	-1.16	2.55	175	-1.16	2.55	91	3.1%	0.00 [-0.25, 0.25]	
Bocanegra 1999	-2.39	2.77	152	-1.16	2.55	91	3.0%	-0.46 [-0.72, -0.19]	
Bocanegra 1999	-1.3	3.04	175	-1.3	3.04	91	3.1%	0.00 [-0.25, 0.25]	
Bocanegra 1999	-2.87	3.04	154	-1.3	3.04	91	3.0%	-0.51 [-0.77, -0.25]	
Bocanegra 1999	-2.55	2.82	152	-1.3	3.04	91	3.0%	• • •	
-		2.02	200	-1.3	2.55	199		-0.43 [-0.69, -0.17]	
dcKenna 2001a deKenna 2001a	-3.6	2.74	200	-2.4	2.55	199	3.3%	-0.45 [-0.65, -0.25]	
McKenna 2001a	-3.7						3.3%	-0.49 [-0.69, -0.29]	
Bimon 2009	-7	4.8	151 2466	-4.7	4.4	155	3.2%	-0.50 [-0.73, -0.27]	•
Subtotal (95% CI)						1573	41.0%	-0.42 [-0.52, -0.32]	•
Heterogeneity: Tau ² =	•				= 0.008)); I* = 6I	3%		
est for overall effect:	Z = 8.38	(P < 0.	00001)						
54.2.2 Non-Flare Des	ign								
Altman 1998	25	27	143	28	27	156	3.2%	-0.11 [-0.34, 0.12]	-+
ltman 1998	34	28	160	40	28	165	3.2%	-0.21 [-0.43, 0.00]	
Altman 1998	24	28	119	24	26	129	3.1%	0.00 [-0.25, 0.25]	
Bourgeois 1994	36	20.1	96	45.2	22.4	97	2.9%	-0.43 [-0.72, -0.15]	
Bourgeois 1994	28.5	18.4	91	40.2	19.5	93	2.9%	-0.61 [-0.91, -0.32]	
3ourgeois 1994	33.8	22.4	91	40.2	19.5	93	2.9%	-0.30 [-0.59, -0.01]	
3ourgeois 1994	30.2	18.8	89	40.2	19.5	93	2.9%	-0.52 [-0.82, -0.22]	
Bourgeois 1994	36.3	20.2	95	45.2	22.4	97	2.9%	-0.42 [-0.70, -0.13]	
Bourgeois 1994	40.9	22.4	94	45.2	22.4	97	2.9%	-0.19 [-0.48, 0.09]	_ _
Broell 1984	27.4	19.6	19	49.1	28.2	20	1.4%	-0.87 [-1.53, -0.21]	
Dreiser 1993a	38.9	15.6	30	50.6	14.9	30	1.8%	-0.76 [-1.28, -0.23]	
Haghighi 2005	28	21.5	40	56.5	22.8	40	2.0%	-1.27 [-1.76, -0.79]	
Kruger 2007	45.2	22.2	56	58.5	21.6	40	2.3%	-0.60 [-1.01, -0.19]	
Vunes 2005	17.84		36	54.82		41	1.8%	-1.66 [-2.18, -1.13]	
Nunes 2005 Nunes 2005	10.25		36	57.29		41	1.6%	• • •	
	35	20.5	78	- 17.29 46	23.73	79		-2.33 [-2.91, -1.74]	
Sandelin 1997	30 35				22.1		2.7%	-0.51 [-0.83, -0.20]	
Sandelin 1997		21.7	78	40		79	2.8%	-0.23 [-0.54, 0.09]	
Schnitzer 2004	6.4	4	96	8.1	3.6	95	2.9%	-0.44 [-0.73, -0.16]	
Schnitzer 2004	5.7	3.9	97	8.1	3.6	95	2.9%	-0.64 [-0.93, -0.35]	
Schnitzer 2004	6.4	4.1	96	8.1	3.6	95	2.9%	-0.44 [-0.73, -0.15]	
Schnitzer 2004	6.8	3.9	95	8.1	3.6	95	2.9%	-0.35 [-0.63, -0.06]	
Shipley 1983	41.5	29	33	61	27.6	33	1.9%	-0.68 [-1.18, -0.18]	
Fuzun 2005	3.4	1.7	14	5.1	2.7	13	1.1%	-0.74 [-1.52, 0.05]	
Fuzun 2005 Subtotal (95% CI)	7.3	2.2	12 1794	5.1	2.7	13 1830	1.0% 59.0%	0.86 [0.03, 1.69] - 0.53 [-0.69, -0.37]	•
Heterogeneity: Tau² = Test for overall effect:	•		•	,	9 < 0.00	001); I²	= 81%		
Fotal (95% CI)			4260			3/02	100.0%	-0.47 [-0.57, -0.37]	▲
Heterogeneity: Tau ² =	: 0.06° CI	hj² = 14		(= 36 (P	۱۹۵۱ - ۱۹			-0.41 [-0.51, -0.51]	• • • · · · · · ·
Fest for overall effect:			•		. 0.00	0017,1	- 10.0		-2 -1 0 1 2
Control Overall ellett.	2 - 0.40	V ~ 0.1	00001)						Favours NSAID Favours Placebo

Outcome	Ν	Flare Trial Design		Ν	Non-Flare Trial Desi	gn	Difference between flare
		Effect size; 95% CI	Statistical Heterogeneity (Chi ² P-value/I ² %)		Effect size; 95% CI	Statistical Heterogeneity (Chi ² P- value/I ² %)	and non-flare (Chi ² ; I ²)
Absolute Pain	13	-0.42 [-0.52, -0.32]	$P = 0.008; I^2 = 56\%$	24	-0.53 [-0.69, -0.37]	$P < 0.00001; I^2 = 81\%$	$P = 0.23; I^2 = 29.4\%$
Mean change in pain score	48	-0.43 [-0.48, -0.38]	$P < 0.00001; I^2 = 59\%$	37	-0.56 [-0.71, -0.42]	$P < 0.00001; I^2 = 94\%$	$P = 0.08; I^2 = 66.4\%$
Absolute functional score	10	-0.40 [-0.47, -0.33]	$P = 0.28; I^2 = 18\%$	8	-0.13 [-0.43, 0.18]	$P < 0.00001; I^2 = 85\%$	$P = 0.08; I^2 = 67.4\%$
Mean change in functional score	38	-0.51 [-0.61, -0.41]	$P < 0.00001; I^2 = 87\%$	39	-0.58 [-0.67, -0.48]	$P < 0.00001; I^2 = 86\%$	$P = 0.34; I^2 = 0\%$
Absolute stiffness score	2	-0.48 [-0.67, -0.30]	$P = 0.23; I^2 = 31\%$	7	-0.49 [-0.66, -0.31]	$P = 0.22; I^2 = 27\%$	$P = 1.00; I^2 = 0\%$
Mean change in stiffness score	27	-0.38 [-0.44, -0.31]	$P = 0.0005; I^2 = 54\%$	16	-0.35 [-0.50, -0.20]	$P < 0.00001; I^2 = 84\%$	$\begin{array}{c} P = 0.75; I^2 = \\ 0\% \end{array}$

Table 1: Flare versus non-flare trial design meta-analysis results by outcome measure.

CI – confidence intervals; I^2 – inconsistency value; vs. - versus

Outcome	Follow-	Ν	Flare Trial Design		N	Non-Flare Trial De	sign	Difference between flare and
	up interval (weeks)		Effect size [95% CI]	Statistical Heterogeneity (Chi ² P-value/I ² %)		Effect size [95% CI]	Statistical Heterogeneity (Chi ² P-value/I ² %)	non-flare (Chi ² ; I ²)
Absolute Pain	0 - 1	0	N/E	N/E	8	-0.56 [-0.82, -0.31]	P < 0.0001; 78%	N/E
	2-4	4	-0.36 [-0.59, -0.13]	P = 0.01; 72%	15	-0.55 [-0.77, -0.34]	P < 0.00001; 82%	P = 0.24; 28.9%
	6 - over	9	-0.44 [-0.55, -0.34]	P = 0.06; 47%	2	-0.15 [-0.48, 0.18]	P = 0.11; 60%	P = 0.10; 62.1%
Mean change in	0 - 1	4	-0.35 [-0.48, -0.23]	P = 0.31; 16%	0	N/E	N/E	N/E
pain score	2-4	8	-0.44 [-0.50, -0.37]	P = 0.97; 0%	14	-0.69 [-1.01, -0.37]	P < 0.00001; 97%	P = 0.13; 56.5%
6 - ov	6 - over	35	-0.44 [-0.51, -0.37]	P < 0.00001; 68%	23	-0.47 [-0.60, -0.34]	P < 0.00001; 88%	P = 0.71; 0.0%
Absolute	0 - 1	0	N/E	N/E	2	0.77 [-1.25, 2.79]	P < 0.00001; 96%	N/E
functional score	2-4	2	-0.34 [-0.47, -0.21]	P = 0.76; 0%	6	-0.32 [-0.54, -0.10]	P = 0.01; 67%	P = 0.85; 0.0%
	6 - over	8	-0.43 [-0.51, -0.34]	P = 0.20; 28%	0	N/E	N/E	N/E
Mean change in	0 - 1	4	-0.26 [-0.38, -0.15]	P = 0.59; 0%	3	-0.47 [-0.64, -0.31]	P = 0.40; 0%	P = 0.04; 75.6%*
functional score	2-4	7	-0.86 [-1.29, -0.42]	P < 0.00001; 97%	14	-0.68 [-0.85, -0.50]	P < 0.00001; 87%	P = 0.45; 0.0%
	6 - over	27	-0.46 [-0.52, -0.39]	P = 0.0003; 56%	22	-0.55 [-0.68, -0.42]	P < 0.0001; 86%	P = 0.23; 31.4%
Absolute	0 - 1	0	N/E	N/E	1	-0.84 [-1.50, -0.18]	P = 0.01; N/E	N/E
stiffness score	2-4	0	N/E	N/E	6	-0.46 [-0.63, -0.29]	P = 0.23; 27%	N/E
	6 - over	2	-0.48 [-0.67, -0.30]	P = 0.23; 31%	0	N/E	N/E	N/E
Mean change in	0 - 1	0	N/E	N/E	0	N/E	N/E	N/E
stiffness score	2-4	7	-0.31 [-0.38, -0.24]	P = 0.94; 0%	4	-0.11 [-0.42, 0.20]	P < 0.0001; 86%	P = 0.21; 37.2%

Table 2: Flare versus non-flare trial design meta-analysis results as assessed by immediate, short, and longer-term follow-up intervals.

6 -	- over	20	-0.41 [-0.50, -0.32]	P < 0.0001; 64%	12	-0.43 [-0.61, -0.26]	P < 0.0001; 83%	P = 0.81; 0.0%

* - signified analysis reach a statistical significant difference; CI – confidence intervals; I2 – inconsistency value; N – number of studies; N/E – Not estimatable; vs. - versus

Outcome	Follow-up interval	Ν	Flare and Possible Fla	re Trial Design	N	Not Flare Trial Des	ign	Difference between flare and possible
	(weeks)		Effect size [95% CI]	Statistical Heterogeneity (Chi ² P-value/I ² %)		Effect size [95% CI]	Statistical Heterogeneity (Chi ² P-value/I ² %)	flare to non-flare (Chi ² ; I ²)
Absolute Pain	0 - 1	2	-0.25 [-1.21, 0.70]	P = 0.004; 88%	8	-0.56 [-0.82, -0.31]	P < 0.0001; 78%	P = 0.54; 0%
	2-4	11	-0.39 [-0.59, -0.20]	P < 0.0001; 75%	15	-0.55 [-0.77, -0.34]	P < 0.00001; 82%	P = 0.28; 14.4%
	6 - over	6	-0.85 [-1.15, -0.55]	P < 0.00001; 97%	2	-0.40 [-0.74, -0.06]	P = 0.91; 0%	P = 0.05; 74.6%*
Mean change in	0 - 1	1	-0.52 [-0.99, -0.05]	P = 0.03; N/E	0	N/E	N/E	N/E
pain score	2-4	8	-0.36 [-0.46, -0.26]	P = 0.11; 41%	14	-0.69 [-1.01, -0.37]	P < 0.00001; 97%	P = 0.05; 73.3%*
	6 - over	20	-0.34 [-0.40, -0.27]	P = 0.02; 44%	23	-0.47 [-0.60, -0.33]	P < 0.00001; 89%	P = 0.08; 67.5%
Absolute	0 - 1	1	0.20 [-0.20, 0.61]	P = 0.32	2	0.77 [-1.25, 2.79]	P < 0.00001; 96%	P = 0.59; 0%
functional score	2-4	5	-0.30 [-0.55, -0.06]	P = 0.06; 56%	6	-0.32 [-0.54, -0.10]	P = 0.01; 67%	P = 0.95; 0%
	6 – over	5	-0.28 [-0.57, 0.00]	P = 0.02; 65%	0	N/E	N/E	N/E
Mean change in	0 - 1	0	N/E	N/E	3	-0.47 [-0.64, -0.31]	P = 0.40; 0%	N/E
functional score	2-4	4	-0.28 [-0.38, -0.19]	P = 0.49; 0%	14	-0.68 [-0.85, -0.50]	P < 0.00001; 87%	P < 0.01; 93.5%*
	6 - over	16	-0.35 [-0.42, -0.28]	P = 0.01; 50%	22	-0.55 [-0.68, -0.42]	P < 0.00001; 86%	P = 0.01; 84.9%*
Absolute	0 - 1	1	0.22 [-0.18, 0.62]	P = 0.28	1	-0.84 [-1.50, -0.18]	P = 0.01	P = 0.01; 86.3%*
stiffness score	2-4	4	-0.61 [-1.47, 0.25]	P < 0.0001; 87%	6	-0.46 [-0.63, -0.29]	P = 0.23; 27%	P = 0.74; 0%
	6 - over	0	N/E	N/E	0	N/E	N/E	N/E
Mean change in	0 - 1	0	N/E	N/E	0	N/E	N/E	N/E
stiffness score	2-4	7	-0.31 [-0.38, -0.24]	P = 0.94; 0%	4	-0.11 [-0.42, 0.20]	P < 0.0001; 86%	P = 0.21; 37.2%

Table 3: Flare and possible flare versus non-flare trial design meta-analysis results as assessed by immediate, short and longer-term follow-up intervals.

6 - over	8	-0.61 [-0.74, -0.48]	P < 0.00001; 84%	12	-0.59 [-0.73, -0.45]	P < 0.00001; 89%	P = 0.83; 0%


* - signified analysis reach a statistical significant difference; CI – confidence intervals; I2 – inconsistency value; N/E – Not estimatable; vs. - versus

Table 4: Meta-regression of effect size of NSAIDs for osteoarthritis pain (number of observation=125)


	В	(95% Confidence Intervals)	P-value
Flare design (yes=1, all others=0)	0.033	(-0.184, 0.251	0.763
Setting (community yes=1, all others=0)	0.324	(-0.154, 0.802)	0.182
Allocation concealment (yes=1, all others=0)	-0.030	(-0.260, 0.200)	0.798
Blinding to participants (yes=1, all others=0)	-0.056	(-0.704, 0.592)	0.864
Intent to treat analysis (yes=1, no=0)	0.076	(-0.167, 0.319)	0.538
Sample size (>=100 per arm vs. <100 per arm)	0.205	(-0.015, 0.424)	0.067
_cons	-0.617	(-1.238, 0.004)	0.051

 β – meta-regression value; p-value – probability value

Supplementary Figure 1: PRISMA flow-chart



Supplementary Figure 2: Funnel plot assessing small sample size publication bias for primary outcome measure (mean change in pain score) for flare versus non-flare trial design.



Supplementary Table 1: MEDLINE search strategy

- 1. osteoarthritis.mp. or exp osteoarthritis/
- 2. arthrosis.mp.
- 3. osteoarthr\$.mp.
- 4. (degenerative adj2 arthritis).mp.
- 5. gonarthrosis.mp.
- 6. coxarthrosis.mp.
- 7. or/1-6
- 8. randomized controlled trial.pt.
- 9. controlled clinical trial.pt.
- 10. randomized.ab.
- 11. placebo.ab.
- 12. clinical trials as topic.sh.
- 13. randomly.ab.
- 14. trial.ti.
- 15. or/8-14
- 16. (animals not (humans and animals)).sh.
- 17. 15 not 16
- 18. exp Anti-Inflammatory Agents, Non-Steroidal/ 164
- 19. NSAIDs.mp.
- 20. cyclooxygenase.mp.
- $21. \ cox^* \ inhibitor.mp.$
- 22. *coxib/
- 23. Lodine.mp.
- 24. celecoxib.mp.
- 25. Celebrex.mp.
- 26. rofecoxib.mp.
- 27. Vioxx.mp.
- 28. meloxicam.mp.
- 29. Mobic.mp.
- $30. \ *Naprosyn/$
- 31. Anaprox*.mp.
- 32. Naprapac Aleve.mp.
- 33. (Cataflam or Voltaren or Arthrotec or Pennsaid).mp.
- 34. lumiracoxib.mp.
- 35. etoricoxib.mp.
- 36. Motrin.mp.
- 37. Profen.mp.
- 38. Vicoprofen.mp.
- 39. Combunox.mp.
- 40. Advil.mp.
- 41. Dolobid.mp.
- 42. Nalfon.mp.
- 43. Ansaid.mp.
- 44. indometacin.mp.
- 45. Indocin.mp.
- 46. Indo-Lemmon.mp.
- 47. Indomethagan.mp.
- 48. Oruvail.mp.
- 49. Toradol.mp.

Supplementary Table 1: MEDLINE search strategy (cont)

- 50. Mefenamic Acid.mp. or exp Mefenamic Acid/
- 51. Ponstel.mp.
- 52. Nabumetone.mp.
- 53. Relafen.mp.
- 54. Oxaprozin.mp.
- 55. Daypro.mp.
- 56. Piroxicam.mp. or exp Piroxicam/ $% \left({{{\rm{P}}_{{\rm{P}}}}} \right)$
- 57. Feldene.mp.
- 58. Sulindac.mp. or exp Sulindac/
- 59. Clinoril.mp.
- 60. Tolmetin.mp. or exp Tolmetin/
- 61. Tolectin.mp.
- 62. Valdecoxib.mp.
- 63. Bextra.mp.
- 64. Diacerein.mp.
- 65. Diacerhein.mp.
- 66. Rhein.mp.
- 67. Anthraquinones.mp. or exp Anthraquinones/
- 68. Diacetyilrhein.mp.
- 69. ART 50.mp.
- 70. Cyclooxygenase Inhibitors.mp. or exp Cyclooxygenase Inhibitors/
- 71. exp Cyclooxygenase Inhibitors/ or exp Cyclooxygenase 2 Inhibitors/
- 72. exp Aspirin/ or Aspirin.mp.
- 73. Etodolac.mp. or exp Etodolac/
- 74. naproxen.mp. or exp Naproxen/
- 75. Diclofenac.mp. or exp Diclofenac/
- 76. Ibuprofen.mp. or exp Ibuprofen/
- 77. Diflunisal.mp. or exp Diflunisal/
- 78. Fenoprofen.mp. or exp Fenoprofen/
- 79. Flurbiprofen.mp. or exp Flurbiprofen/
- 80. Indomethacin.mp. or exp Indomethacin/
- 81. Ketoprofen.mp. or exp Ketoprofen/
- 82. exp Ketorolac/ or Ketorolac.mp.
- 83. or/18-82
- 84. and/7,17,83

Study	Funding (Public/ Industry/ Unclear)	Washout period specified	Flare Design Clearly Stated	Definition of Flare Design
Altman [21]	Unclear	\checkmark	Х	No information provided.
Baerwald [45]	Industry	\checkmark	✓	To be eligible for inclusion, patients had to have experienced a flare of pain at the baseline visit (defined as a score of 50 mm for question 1 of the WOMAC pain subscale [17] that was increased by 15 mm as compared with the screening visit)."
Bensen [19]	Industry	✓	✓	OA was considered symptom-active if the patient's and physician's global assessment scores were "fair," "poor," or "very poor" and if 3 of the following 4 criteria were present: (1) a patient's assessment of arthritis pain (VAS) measurement of 40 mm or higher, (2) an increase of 2 points or more in the OA Severity Index from the screening assessment; (3) an increase from the screening visit of 1 grade or more in the patient's global assessment; and (4) an increase from the screening visit of 1 grade or more in the physician's global assessment. For patients not receiving NSAID or analgesic therapy and who had uncontrolled OA, 3 of the following 4 conditions were necessary for randomization at the baseline visit: (1) a patient's assessment of arthritis pain (VAS) measurement of 40 mm or higher, (2) an OA Severity Index score of 7 or more; (3) a patient's global assessment grade of poor or very poor, and (4) a physician's global assessment grade of poor or very poor
Biegert [65]	Public	\checkmark	Х	No information provided.
Bingham [38]	Industry	V	\checkmark	NSAID users had to demonstrate a minimum score of 40mm with an increase of 15mm on patient-assessed pain walking on a flat surface, and Eligibility required patients to meet specific flare criteria upon medication washout. IGADS worsening of at least one point on a 5-point Likert scale. Acetaminophen users had to demonstrate a minimum of 40mm of patient-assessed pain walking on a flat surface, fair, poor or very poor on IGADS, and a minimum of 40mm on PGADS.
Bocanegra [28]	Industry	V	\checkmark	Worsening of the OA symptoms was defined as at least 2 of the following 3: (1) an increase of one grade or more since screening, or a score of "poor" or "very poor," on the physician's Global Assessment"; (2) an increase of at least one grade since screening, or a score of "poor" or "very poor," on the patient's Global Assessment"; and (3) an increase of at least 2 points since screening, or a score of 7 or higher, on the Osteoarthritis Severity Index
Bourgeois [16]	Unclear	\checkmark	Х	No information provided.
Case [63]	Public	\checkmark	Х	No information provided.
Cryer [46]	Industry	\checkmark	\checkmark	Patients had a wash-out period of 7-14 days, a baseline visit (following a flare in OA pain)
Davies [56]	Industry	\checkmark	Possible	No information provided.
Day [30]	Industry	\checkmark	\checkmark	patients were randomized to the study if they reported a minimum of 40mm and an increase of 15 mm on the VAS compared with the value at the screening visit
DeLemos [75]	Industry	\checkmark	Х	No information provided.
Dickson [60]	Industry	\checkmark	Х	No information provided.

Ding [74]	Public	Unclear	Possible	No information provided.
Dougados [72]	Industry	\checkmark	Х	No information provided.
Dreiser [52]	Unclear	\checkmark	Х	No information provided.
Ehrich [29]	Industry	v	✓	Patients were randomized to the study if they reported a minimum of 40 mm on a 100 mm OA pain VASVAS (0 mm = no pain; 100 mm = extreme pain) after discontinuation of NSAID therapy, and an increase of 15 mm compared with the value recorded at the screening visit
Ehrich [31]	Unclear	V	\checkmark	To be eligible, patients had to demonstrate worsening in pain after discontinuation of previous therapy with NSAIDs
El-Mehairy [49]	Unclear	\checkmark	Х	No information provided.
Essex [48]	Industry		\checkmark	 African American patients aged ≥ 45 years, with OA of the knee (diagnosed according to American College of Rheumatology guidelines30) in a flare state, and with a functional capacity classification of I – III were eligible for study participation." "For patients receiving NSAID or analgesic therapy, a flare was demonstrated if the physician's Global Assessment of Arthritis and the patient's Global Assessment of Arthritis were both 'fair', 'poor' or 'very poor' at the baseline visit, and if the baseline Patient's Assessment of Arthritis Pain VAS measurement was between 40 and 90 mm (out of 100 mm; 0 representing no pain and 100 representing very severe pain), the patient's Global Assessment of Arthritis showed an increase of one or more grades and the physician's Global Assessment of Arthritis showed an increase of one or more grades." "For patients who were not receiving treatment, a flare was defined if the Patient's Assessment of Arthritis was 'poor' or 'very poor' or 'very poor', and the Global Assessment of Arthritis was 'poor' or 'very poor' or 'very poor', and the Global Assessment of Arthritis was 'poor' or 'very poor'."
Fleischmann [36]	Industry	~	\checkmark	At the end of the screening period, patients with pain intensity (during the last 24 hours) in the targeted knee >=40 mm on a 100 mm VAS were eligible for entry into the treatment phase
Gibofsky [64]	Industry	X	X	No information provided.
Goldstein [58]	Unclear	Unclear	Possible	No information provided.
Grifka [35]	Industry	V	V	Patients were required to have pain intensity a 40 mm on a 100 mm VAS(most pain) in the target hand during the 24 hours prior to baseline. An increase in pain intensity in the target hand of either a 20% or a 10 mm VAS at the baseline visit com-pared with screening values (whichever was greater) was required to assess those patients who required analgesia
Haghighi [68]	Unclear	\checkmark	X	No information provided.
Karlsson [43]	Industry	~	✓	Patients were also required to experience a pain flare within 3–14 days of discontinuing all pain medications during a washout phase (between screening and baseline). The VAS pain score for pain on walking on a flat surface at baseline was required to be ≥ 40 mm, with an increase of at least 15 mm compared to screening
Kivitz [62]	Industry	\checkmark	Possible	No information provided.
Kruger [73]	Unclear	\checkmark	Х	No information provided.
Lee [51]	Industry	\checkmark	Possible	No information provided.
Leung [34]	Industry	\checkmark	✓	The flare criteria were: 40 mm and an increase of 15mm compared with screening values on question 1 of WOMAC questionnaire and a worsening on the investigator's global assessment of disease status by 1 point on a

				5-point Likert scale. Pre-study paracetamol (acetaminophen) users had to demonstrate reproducible symptoms or the screening and randomization visits: of 40 mm pain while walking on a flat surface and patient's global assessment of disease status
Lund [55]	Unclear	\checkmark	X	No information provided.
McKenna [32]	Industry	\checkmark	\checkmark	OA evidenced by a defined worsening of the signs and symptoms of the disease following discontinuation of treatment with NSAIDs for other analgesic medications.
Nguyen [53]	Industry	\checkmark	Possible	No information provided.
Nunes [22]	Unclear	X	Х	No information provided.
Paul [17]	Unclear	Unclear	X	No information provided.
Petersen [76]	Public	\checkmark	Possible	No information provided.
Pincus [15]	Unclear	\checkmark	X	No information provided.
Puopolo [40]	Industry	 ✓ 	✓	A sufficient flare within the washout period was defined as a patient-reported pain score of at least 40 mm while the patient walked on a flat surface, and was at least 15 mm greater than that recorded at the pre-study visit as well as a worsening of at least one point (0- to 5-point Likert scale) for IGADS
Reginster [41]	Unclear	\checkmark	\checkmark	Pre-study NSAID users were required to demonstrate worsening of pain (flare) after a pre-specified washout period based on the half-life of the drug
Rother [42]	Industry	\checkmark	\checkmark	Patients had to meet three osteoarthritis flare criteria
Sandelin [54]	Unclear	X	X	No information provided.
Schmitt [57]	Unclear	\checkmark	Possible	No information provided.
Schnitzer [47]	Industry	✓	\checkmark	Patient had experienced a flare of pain (Baseline WOMAC: question 1 of pain subscale value of 50 mm, with an increase of 15 mm compared with screening) after discontinuing all analgesic therapy at screening (for at least 5 half-lives of the prior analgesic or anti-inflammatory therapy before the baseline visit)."
Schnitzer [66]	Industry	\checkmark	Х	No information provided.
Schnitzer [77]	Public	\checkmark	Possible	No information provided.
Scott [59]	Unclear	\checkmark	Possible	No information provided.
Sheldon [69]	Unclear	\checkmark	X	No information provided.
Shipley [50]	Industry	X	X	No information provided.
Simon [44]	Industry	\checkmark	\checkmark	Patients had to meet the osteoarthritis flare criteria
Svensson [71]	Industry	X	Х	No information provided.
Tannenbaum [65]	Industry	\checkmark	X	No information provided.
Truitt [18]	Industry	\checkmark	X	No information provided.
Tuzun [70]	Unclear	Unclear	X	No information provided.
Uzun [61]	Not stated	Unclear	Possible	No information provided.
Wiesenhutter [37]	Industry	\checkmark	\checkmark	A flare was classified as sufficient if the minimum patient-reported pain score was 40mm while the patient waked on a flat surface
Williams [33]	Industry	\checkmark	\checkmark	All patients included in this study experienced an OA flare at the baseline visit (day 0, within 24 hours before the first dose of study medication)."

				"Patients were considered to have an OA flare if baseline scores on both the Patient's and Physician's Global Assessments of Arthritis indicated that their condition was fair, poor, or very poor. Furthermore, baseline assessments had to meet the following criteria: Patient's Assessment of Arthritis Pain-VAS measurement of 240 mm; an increase of 22 points on the Lequesne Osteoarthritis Severity Index versus values at the screening visit; and an increase of 21 grade on the Patient's or Physician's Global Assessment of Arthritis versus values at the screening visit." "Patients with uncontrolled OA who were not receiving NSAIDs or analgesics before the study were considered to be experiencing an OA flare and therefore eligible for enrolment if they satisfied the following criteria: Patient's Assessment of Arthritis Pain-VAS measurement of 240 mm, a Lequesne Osteoarthritis Severity Index score of 27, and a score on the Patient's or Physician's Global Assessment of Arthritis of 4 (poor) or 5 (very poor)."
Wittenberg [39]	Industry	\checkmark	\checkmark	Patients were required to have VAS actual pain intensity at baseline of \geq 50 mm for the most severely affected (target) knee joint after activity. (The pain requirement at baseline following washout [\geq 50 mm] was greater than at screening [\geq 40 mm]; thus, an increase in pain from screening to baseline was required for study entry.)

✓ - Yes; X – No; IGADS - Investigator Global Assessment of Disease Status; mm – millimetres; NSAIDs – non-steroidal anti-inflammatory drugs; OA – osteoarthritis; VAS
 – visual analogue scale; WOMAC - Western Ontario and McMaster Universities Osteoarthritis Index.

Study	NSAIDs and Dose	Duration of NSAID (weeks)	Contaminant	N	Mean Age	Gender (M/F)	Joint Affected	Mean disease duration (years)	Setting (Hospital/Community)
Altman [21]	Naproxen 500 mg BID	26	Acetaminophen	333	64	143/190	Knee	Unclear	Hospital
Baerwald [45]	Naproxcinod 750 mg BID Naproxen 500 mg BID	13	Acetaminophen	810	63	279/531	Hip	Unclear	Hospital
Bensen [19]	Celecoxib, 50 mg BID Celecoxib, 100 mg BID Celecoxib, 200 mg BID Celecoxib, 500 mg BID	1	Acetaminophen, aspirin	1003	62.2	281/722	Knee	9.8	Hospital
Biegert [65]	Diclofenac, 2 tablets BID100 mg/day	6	Aspirin, physical therapy	84	61.8	53/31	Knee/Hip	Unclear	Hospital
Bingham [38]	Etoricoxib 30 mg QD Celecoxib 200 mgQD	12	Acetaminophen	599	62.4	195/404	Knee/Hip	Unclear	Unclear
	Eetoricoxib 30 mg QD Celecoxib 200 mg QD	12	Acetaminophen	608	61.8	209/399	Knee/Hip	Unclear	Unclear
Bocanegra [28]	Diclofenac sodium 75 mg BID Diclofenac/misoprostol D50/M200 TID Diclofenac/misoprostol D75/M200 BID	6	Unclear	572	62.5	180/392	Knee/Hip	11.2	Hospital

Supplementary Table 3: Participant characteristics of the included studies (medications and demographics)

Bourgeois [16]	Nimesulide 50 mg BID	4	Paracetamol				Knee	Unclear	Unclear
	Nimesulide 100 mg BID	_							
	Nimesulide 200 mg BID	_		382	u	Unclear			
Case [63]	Diclofenac sodium 75 mg BID	12	Unclear	82	62.2	41/41	Knee	Unclear	Hospital
Cryer [46]	Naproxen/esomeprazel magnesium tablets BID	12	Prednisone, antiplatelet agents	612	61.6	221/391	Knee	Unclear	Hospital
	Celecoxib 200mg capsules QD		, antacid, acetaminophen						
Davies [56]	Ibuprofen 800 mg TID	4	Acetaminophen				Knee/Hip/	7.9	Hospital
				104	61.5	38/66	Spine		
Day [30]	Rofecoxib 12.5 mg QD	6	Acetaminophen	809	63.6	162/647	Knee/Hip	8.7	Hospital
	Rofecoxib 25 mg QD	-							
	Ibuprofen 800 mg TID	-							
DeLemos [75]	Celecoxib 200 mg QD	12	Aspirin, acetaminophen				Knee/Hip	8.1	Hospital
				1001	58	369/632			
Dickson [60]	Diclofenac 100mg/day, 3 weekly arthrocenteses	3	Acetaminophen				Knee	Unclear	Community
				165	64.5	73/92			

Ding [74]	Ibuprofen, 0.3g, BID	2	Health education	90	56	25/65	Knee	4.7	Hospital
Dougados [72]	Lumiracoxib 100 mg QD Lumiracoxib 100 mg QDwith initial dose	13	Sheldon 2005: acetaminophen				Knee	5.5	Unclear
	Celecoxib 200 mg QD			3235	61.5	1097/2138			
Dreiser [52]	Ibuprofen 800 mg QD	2	Unclear	60	59.4	9/51	Hand	Unclear	Hospital
Ehrich [31]	Rofecoxib 5 mg QD	6	None	672	61.7	195/477	Knee/Hip	10.9	Unclear
	Rofecoxib 12.5 mg QD								
	Rofecoxib 25 mg QD								
	Rofecoxib 50 mg QD								
Ehrich [29]	Rofecoxib 25 mg QD	6	Acetaminophen	219	63.5	63/156	Knee	11.9	Hospital
	Rofecoxib 125 mg QD								
El-Mehairy [49]	Nifiumic acid 250 mg TID	8	Unclear				Knee/Hip	Unclear	Hospital
	Phenylbutazone (100 mg/capsule), NSAIDs, TID								
	Oxyphenylbutazon 100 mg, NSAIDs, TID			100	54.6	14/86			
Essex [48]	Celecoxib 200 mg QD	6	Aspirin,	322	58	64/258	Knee	5.4	Hospital
	Naproxen 500 mg BID		acetaminophen				Knee/Hip	-	
Fleischmann	Lumiracoxib 200 mg oQD	13	Paracetamol	1600	61.1	539/1061	Knee	6.4	Hospital
[36]	Lumiracoxib 400 mg QD								

	Celecoxib 200 mg QD									
Gibofsky [64]	Celecoxib 200 mg/day	6	Aspirin, acetaminophen				Knee	8.6	Unclear	
	Rofecoxib 25 mg/day		acetaninophen	477	62.9	157/320				
Goldstein [58]	Naproxen 375 mg daily week	3	Acetaminophen				Knee/Hip	Unclear	Hospital	
	1, week 2-3: naproxen 375 mg BID			194	61.2	72/122				
Grifka [35]	Lumiracoxib 200 mg QD	4	Paracetamol	594	61.9	104/490	Hand	5.3	Hospital	
	Lumiracoxib 400 mg QD	-								
Haghighi [68]	Ibuprofen three 400 mg	4	Acetaminophen				Knee/Hip	Unclear	Hospital	
	tablets daily			120	56.8	89/31				
Karlsson [43]	Naproxcinod 750mg QD	6	Paracetamol,	543	61.5	177/366	Knee/Hip	Unclear	Hospital	
	Naproxcinod 750mg BID	1	antihypertensive drugs							
	Naproxcinod 1125mg BID	_								
	Rofecoxib 25 mg QD	-								
Kivitz [62]	Valdecoxib 5 mg QD	12	Unclear				Knee	9.1	Community	
	Valdecoxib 10 mg QD	-								
	Valdecoxib 20 mg QD	-								
	Naproxen 500 mg BID	-		1015	59.7	356/659				
Kruger [73]	Oxaceprol 200 mg TID	3	Acetaminophen	97	59.6	31/66	Knee/Hip	Unclear	Hospital	
Lee [51]	Diflunisal 500 mg BID	6	None				Knee	5	Unclear	
	Diflunisal 375 mg BID	-		422	61.3	139/283				
Leung [34]	Etoricoxib 60 mg QD	12	Paracetamol	501	63.2	109/392	Knee/Hip	6.1	Hospital	

	Naproxen 500 mg BID								
Lund [55]	Meloxicam 7.5 mg	3	Paracetamol, message, exercise	411	68.5	112/299	Knee	Unclear	Hospital
McKenna [32]	Celecoxib 100 mg BID Diclofenac 50 mg TID	6	Aspirin	600	61.7	208/392	Knee	8.6	Unclear
Nguyen [53]	Tenoxicam 20 mg QD	8	Paracetamol	145	62.6	62/83	Hip	5.6	Hospital
Nunes [22]	Alginac TIDvitamin b12, b6, b1	2	Unclear	80	42.1	42/38	Knee/Hip	2.2	Unclear
Paul [17]	Aceclofenac (100 mg) BID Nabumetone (750 mg) BID	4	Paracetamol	423	53.5	188/235	Knee	4.3	Hospital
Petersen [76]	Ibuprofen 600mg BID	12	Quadriceps muscle strength, acupuncture	35	62.4	14/21	Knee	Unclear	Hospital
Pincus [15]	Celecoxib 200 mg/day	6	Propoxyphene; codeine 60 mg or tramadol rescue medication	524	U	Unclear	Knee/Hip	Unclear	Unclear
Puopolo [40]	Etoricoxib 30 mg QD Ibuprofen 800 mg TID	12	Acetaminophen	816	62.6	198/618	Knee/Hip	6.6	Hospital
Reginster [41]	Etoricoxib 60 mg QD Naproxen 500 mg BID	12	Paracetamol	997	62.8	279/718	Knee/Hip	Unclear	Unclear
Rother [42]	Celecoxib 100 mg oral and placebo gel	6	Paracetamol	397	62.8	160/237	Knee	Unclear	Hospital
Sandelin [54]	Diclofenac 50 mg BID	4	None	281	61	92/189	Knee	Unclear	Hospital

Schmitt [57]	Diclofenac sodium 150 mg dual release capsules (DRC150) QD	12	None				Knee/Hip	8.8	Hospital
	Diclofenac sodium 75 mg QD								
	Voltaren 50 mg enteric coated tablet (EC50) TID			393	60.9	63/330			
Schnitzer [47]	Naproxcinod 750 mg BID	13	Acetaminophen	1000	59.8	291/709	Knee	Unclear	Unclear
	Naproxcinod 375 mg BID								
	Naproxcinod 500 mg BID								
Schnitzer [66]	Lumiracoxib 50 mg BID	4	Acetaminophen				Knee/Hip	6.9	Unclear
	Lumiracoxib 100 mg BID								
	Lumiracoxib 200 mg BID								
	Lumiracoxib 400 mg BID			583	60.3	187/396			
Schnitzer [77]	Lumiracoxib 100 mg QD	13	Acetaminophen				Hip	Unclear	Unclear
	Celecoxib 200 mg QD			1262	61.6	485/777			
Scott [59]	Tiaprofenic acid 300 mg BID	4	Acetaminophen				Knee	5	Unclear
	Indomethacin 25 mg TID			812	61	240/572			
Sheldon [69]	Lumiracoxib 100 mg QD	13	Acetaminophen	1551	60.5	583/968	Knee	6.9	Hospital
Shipley [50]	Fenoprofen 600 mg TID	2	Paracetamol;				Knee/Hip	Unclear	Hospital
	Rhus tox		homeopathy therapy	33	65	9/24			
Simon [44]	oral diclofenac tablets 100 mg	12	glucosamine, chondroitin, paracetamol	772	61.6	289/483	Knee	Unclear	Hospital

Svensson [71]	Naproxen 500 mg BID	8	Unclear	511	59.7	151/360	Knee	Unclear	Unclear
	Naproxen 500 mg BID	8	Unclear	511	59.7	151/360	Hip	Unclear	Unclear
Tannenbaum	Lumiracoxib 200 mg, QD	13	Paracetamol				Knee	4.8	Unclear
[67]	Lumiracoxib 400 mg, QD	-							
	Celecoxib 200 mg, QD			1702	64.2	536/1166			
Truitt [18]	Rofecoxib 12.5 mg QD	6	Acetaminophen				Knee/Hip	15	Hospital
	Rofecoxib 25 mg QD	-							
	Nabumetone 1500 mg QD			341	83	124/217			
	Flurbiprofen 100 mg PO (tablets) BID	3	Unclear				Knee	5.1	Hospital
Tuzun [70]	Tiaprofenic acid 300 mg PO (tablets) BID			39	59.1	19/20			
Uzun [61]	Flurbiprofen 100 mg BID	3	Unclear				Knee	5.1	Hospital
	Tiaprofenic acid 300 mg BID	-		39	59.1	20/19			
Wiesenhutter [37]	Etoricoxib 30 mg/d	12	Acetaminophen, aspirin, stable	528	61.5	156/372	Knee/Hip	7.8	Unclear
	Ibuprofen 2400mg/d		glucosamine or chondroitin						
Williams [33]	Celecoxib 100 mg BID	6	Aspirin,	718	61.5	214/504	Knee	Unclear	Unclear
	Celecoxib 200 mg QD	1	acetaminophen						
Wittenberg [39]	Lumiracoxib 400 mg QD	1	Acetaminophen	334	65	123/211	Knee	7.5	Unclear
	Celecoxib 200 mg BID	-							

BID – twice a day; F – female; M- Male; mg – milligrams; mg/d – milligrams per day; N – number of participants; PO – orally taken; QD – once a day; TID – three times a day

Study	Randomisation Defined	Allocation concealment	Blinding of participants	Blinding of clinicians	Blinding of assessors	Follow- up >85%	ITT Analysis Performed
Altman [21]	Unclear	Unclear	\checkmark	Х	\checkmark	Х	Unclear
Baerwald [45]	Unclear	Unclear	\checkmark	Unclear	Unclear	Х	\checkmark
Bensen [19]	\checkmark	Unclear	\checkmark	\checkmark	\checkmark	Х	\checkmark
Biegert [65]	\checkmark	Unclear	\checkmark	Unclear	\checkmark	Х	\checkmark
Bingham [38]	Unclear	Unclear	\checkmark	Unclear	Unclear	Х	\checkmark
Bocanegra [28]	Unclear	Unclear	\checkmark	Unclear	Unclear	Х	\checkmark
Bourgeois [16]	\checkmark	Unclear	\checkmark	\checkmark	\checkmark	Х	X
Case [63]	Unclear	Unclear	\checkmark	Unclear	Unclear	Х	\checkmark
Cryer [46]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Davies [56]	Unclear	Unclear	\checkmark	Unclear	Unclear	\checkmark	Х
Day [30]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	Х
DeLemos [75]	Unclear	Unclear	\checkmark	Unclear	Unclear	Х	\checkmark
Dickson [60]	Unclear	Unclear	\checkmark	Х	\checkmark	Х	\checkmark
Ding [74]	\checkmark	\checkmark	Х	Х	Х	\checkmark	\checkmark
Dougados [72]	Unclear	Unclear	\checkmark	Unclear	Unclear	Х	\checkmark
Dreiser [52]	Unclear	Unclear	\checkmark	Unclear	Unclear	\checkmark	\checkmark
Ehrich [29]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	Х	\checkmark
Ehrich [31]	Unclear	Unclear	\checkmark	Unclear	Unclear	Х	\checkmark
El-Mehairy [49]	Unclear	Unclear	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Essex [48]	\checkmark	Unclear	\checkmark	Unclear	Unclear	Х	\checkmark
Fleischmann [36]	Unclear	Unclear	\checkmark	\checkmark	Unclear	Х	\checkmark
Gibofsky [64]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	Х	\checkmark
Goldstein [58]	Unclear	Unclear	\checkmark	Unclear	Unclear	\checkmark	Х
Grifka [35]	Unclear	Unclear	\checkmark	Unclear	Unclear	\checkmark	\checkmark
Haghighi [68]	Unclear	Unclear	\checkmark	Unclear	Unclear	\checkmark	\checkmark
Karlsson [43]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	Х	\checkmark
Kivitz [62]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	Х	\checkmark

Supplementary Table 4: Summary of the included trial quality assessment results

Kruger [73]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	X	\checkmark
Lee [51]	Unclear	Unclear	\checkmark	Unclear	Unclear	X	Х
Leung [34]	\checkmark	\checkmark	\checkmark	\checkmark	Unclear	X	Х
Lund [55]	Unclear	Unclear	\checkmark	Unclear	Unclear	\checkmark	\checkmark
McKenna [32]	Unclear	Unclear	\checkmark	Unclear	Unclear	X	\checkmark
Nguyen [53]	\checkmark	Unclear	\checkmark	✓	√	\checkmark	\checkmark
Nunes [22]	Unclear	Unclear	\checkmark	Unclear	Unclear	\checkmark	Unclear
Paul [17]	Unclear	Unclear	\checkmark	✓	√	X	X
Petersen [76]	\checkmark	\checkmark	\checkmark	✓	√	\checkmark	X
Pincus [15]	Unclear	Unclear	\checkmark	Unclear	Unclear	X	\checkmark
Puopolo [40]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	X	\checkmark
Reginster [41]	\checkmark	\checkmark	\checkmark	Unclear	Unclear	X	X
Rother [42]	\checkmark	\checkmark	\checkmark	\checkmark	Unclear	Х	\checkmark
Sandelin [54]	\checkmark	\checkmark	\checkmark	Unclear	Unclear	\checkmark	\checkmark
Schmitt [57]	Unclear	Unclear	\checkmark	Unclear	Unclear	Х	\checkmark
Schnitzer [47]	Unclear	Unclear	\checkmark	\checkmark	\checkmark	Х	\checkmark
Schnitzer [66]	Unclear	Unclear	\checkmark	Unclear	Unclear	\checkmark	\checkmark
Schnitzer [77]	\checkmark	Unclear	\checkmark	\checkmark	\checkmark	Х	\checkmark
Scott [59]	Unclear	Unclear	\checkmark	X	X	Unclear	Unclear
Sheldon [69]	Unclear	Unclear	\checkmark	Unclear	Unclear	X	✓
Shipley [50]	Unclear	Unclear	\checkmark	✓	Unclear	\checkmark	X
Simon [44]	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	Х	\checkmark
Svensson [69]	Unclear	Unclear	\checkmark	Unclear	Unclear	Unclear	Unclear
Tannenbaum [65]	Unclear	Unclear	\checkmark	Unclear	Unclear	Х	\checkmark
Truitt [18]	\checkmark	\checkmark	\checkmark	✓	\checkmark	X	\checkmark
Tuzun [70]	Unclear	Unclear	Х	X	X	Unclear	Unclear
Uzun [61]	Unclear						
Wiesenhutter [37]	Unclear	Unclear	\checkmark	\checkmark	Unclear	X	\checkmark
Williams [33]	Unclear	Unclear	\checkmark	\checkmark	\checkmark	Х	\checkmark
Wittenberg [39]	Unclear	Unclear	\checkmark	\checkmark	Unclear	\checkmark	\checkmark

 \checkmark - satisfied; X – not satisfied; ITT – intention-to-treat analysis